<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1306233789
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Scemblix
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ASCIMINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        19832.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS Pharma Stein AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS Pharma Stein AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Novartis Europharm Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Scemblix is</strong></p><p>Scemblix contains the active substance asciminib, which belongs to a group of medicines called protein kinase inhibitors.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>What Scemblix is used for</strong></p><p>Scemblix is a prescription medicine used to treat adults with:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; newly diagnosed or previously treated Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ph+ CML in CP with the T315I mutation.</p><p>&nbsp;</p><p><strong style="text-align:unset">How Scemblix works</strong></p><p>In Ph+ CML, the body produces large numbers of abnormal white blood cells. Scemblix blocks the action of a protein (BCR::ABL1) that is produced by these abnormal white blood cells and stops their division and growth.</p><p>If you have any questions about how this medicine works or why this medicine has been prescribed for you, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take Scemblix</strong></p><p>- if you are allergic to asciminib or any of the other ingredients of this medicine (listed in section 6).</p><p><strong>b. Take special care with Scemblix</strong></p><p>Talk to your doctor or pharmacist before taking Scemblix if any of the following applies to you:</p><p>- if you have or have ever had severe upper stomach pain that could be due to problems with your pancreas (inflamed pancreas, pancreatitis).</p><p>- if you have ever had or might now have a hepatitis B infection. This is because Scemblix could cause hepatitis B to become active again. You will be carefully checked by your doctor for signs of this infection before treatment is started.</p><p><strong>Tell your doctor or pharmacist immediately if you get any of the following during treatment with Scemblix:</strong></p><p>- if you experience weakness, spontaneous bleeding or bruising and frequent infections with signs such as fever, chills, sore throat or mouth ulcers. These can be signs of decreased bone marrow activity, resulting in myelosuppression (a reduction in the number of white blood cells, red blood cells and platelets).</p><p>- if blood tests show that you have high levels of enzymes called lipase and amylase (signs of damage to the pancreas, also known as pancreatic toxicity).</p><p>- if you have a heart disorder or a heart rhythm disorder, such as an irregular heartbeat or an abnormal electrical activity of the heart called QT interval prolongation that can be seen on an electrocardiogram (ECG).</p><p>- if blood tests show that you have a low level of potassium or magnesium (hypokalaemia or hypomagnesaemia).</p><p>- if you are being treated with medicines that may have an unwanted effect on the function of the heart (torsades de pointes) (see &ldquo;Other medicines and Scemblix&rdquo;).</p><p>- if you experience headache, dizziness, chest pain or shortness of breath (possible signs of high blood pressure, also known as hypertension).</p><p>&nbsp;</p><p><strong>Monitoring during your treatment with Scemblix</strong></p><p>Your doctor will regularly monitor your condition to check that the treatment is having the desired effect. You will have regular tests including blood tests during treatment. These tests will monitor:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the amount of blood cells (white blood cells, red blood cells and platelets).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the levels of pancreas enzymes (amylase and lipase).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the levels of electrolytes (potassium, magnesium).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your heart rate and blood pressure.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children or adolescents aged under 18 years.</p><p>&nbsp;</p><p><strong>c. Taking other medicines, herbal or dietary supplements</strong></p><p>&nbsp;</p><p>Tell your healthcare provider about all the medicines you take, including prescription and over- the-counter medicines, vitamins, and herbal supplements. SCEMBLIX and other medicines may affect each other causing side effects and may affect the way that SCEMBLIX works.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>d. Taking Scemblix with food and drink</strong></p><p>Do not take this medicine with food. Take it at least 2 hours after and 1 hour before any food. For more information, see &ldquo;When to take Scemblix&rdquo; in section 3.</p><p>&nbsp;</p><p><strong>e. Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><u>Pregnancy</u></p><p>Scemblix may harm your unborn baby. If you are a woman who could become pregnant, your doctor will discuss with you the potential risks of taking it during pregnancy or breast feeding.</p><p>If you are a woman who could become pregnant, your doctor may perform a pregnancy test before starting treatment with Scemblix.</p><p>If you do become pregnant, or think you may be pregnant, after starting treatment with Scemblix, tell your doctor straight away.</p><p><u>Contraceptive advice for women</u></p><p>If you are a woman who could become pregnant, you should use an effective method of contraception during treatment with Scemblix and for at least 3 days after you stop taking it to avoid becoming pregnant. Ask your doctor about effective methods of contraception.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>Breast feeding</u></p><p>It is not known if Scemblix passes into breast milk. Therefore, you should discontinue breast feeding while you are taking it and for at least 3 days after you stop taking it.</p><p>&nbsp;</p><p><strong>f. Driving and using machines</strong></p><p>This medicine has no or negligible influence on the ability to drive and use machines. If you experience side effects (such as dizziness or visual disorders) with a potential impact on the ability to safely drive or use any tools or machines after taking this medicine, you should refrain from these activities until the effect has disappeared.</p><p>&nbsp;</p><p><strong>g. Important information about some of the ingredients of Scemblix</strong></p><p><strong>Scemblix contains lactose and sodium</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &ldquo;sodium free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How much Scemblix to take </strong></p><p>Your doctor will tell you exactly how many tablets you should take per day, and how to take them.</p><p><strong><u>Recommended Dosage in Ph+ CML in CP For once daily dosing:</u></strong></p><p>Take 2 tablets of Scemblix 40 mg once daily at approximately the same time each day. <u>For Twice daily dosing:</u></p><p>Take 1 tablet of Scemblix 40 mg twice per day. Take 1 tablet, then take another one approximately 12 hours later.</p><p>&nbsp;</p><p><strong><u>For patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)</u></strong><strong> <u>in chronic phase (CP) with T315I mutation</u></strong></p><p>The recommended dose is 5 tablets of Scemblix 40 mg twice per day. Take 5 tablets, then take another 5 tablets approximately 12 hours later.</p><p>Depending on how you respond to treatment and on possible side effects, your doctor may ask you to change to a lower dose or to temporarily or permanently stop the treatment.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>When to take Scemblix</strong></p><p>Take Scemblix:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; at least 2 hours after any food</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; then wait at least 1 hour before eating again.</p><p>Taking this medicine at the same time each day will help you to remember when to take it.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>How to take Scemblix</strong></p><p>Swallow the tablets whole with a glass of water. Do not break, crush or chew them to ensure proper dosing.</p><p><strong>How long to take Scemblix</strong></p><p>Continue taking this medicine for as long as your doctor tells you. This is a long term treatment, possibly lasting for months or years. Your doctor will regularly monitor your condition to check that the treatment is having the desired effect.</p><p>If you have questions about how long to take this medicine, talk to your doctor or pharmacist.</p><p><strong>a. If you take more Scemblix than you should</strong></p><p>&bull;&nbsp; If you have taken more tablets than you should have, or if someone else accidentally takes your medicine, contact a doctor for advice straight away. Show them the pack. Medical treatment may be necessary.</p><p><strong>b. If you forget to take Scemblix</strong></p><p>If there are less than 6 hours until your next dose, skip the missed dose and then take the next one as planned.</p><p>If there are more than 6 hours until your next dose, take the missed dose and then take the next one as planned.</p><p>&nbsp;</p><p><strong>c. If you stop taking Scemblix</strong></p><p>Do not stop taking this medicine unless your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>SCEMBLIX may cause serious side effects, including:</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Low blood cell counts. </strong>SCEMBLIX may cause low platelet counts (thrombocytopenia), low white blood cell counts (neutropenia), and low red blood cell counts (anemia). Your healthcare provider will do blood tests to check your blood cell counts every 2 weeks for the first 3 months of treatment and then monthly or as needed during treatment with</p><p>&nbsp;</p><p>SCEMBLIX. Tell your healthcare provider right away if you have unexpected bleeding or easy bruising, blood in your urine or stools, fever, or any signs of an infection.</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pancreas problems. </strong>SCEMBLIX may increase enzymes in your blood called amylase and lipase, which may be a sign of pancreatitis. Your healthcare provider may do blood tests monthly or as needed during treatment with SCEMBLIX to check for problems with your pancreas. Tell your healthcare provider right away if you have severe stomach-area (abdominal) pain or discomfort, nausea, or vomiting.</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>High blood pressure. </strong>Your healthcare provider may check your blood pressure and treat any high blood pressure during treatment with SCEMBLIX as needed. Tell your healthcare provider if you develop elevated blood pressure or symptoms of high blood pressure, including confusion, headaches, dizziness, chest pain, or shortness of breath.</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Allergic reaction. </strong>Stop taking SCEMBLIX and get medical help right away if you get any signs or symptoms of an allergic reaction, including:</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble breathing or swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, or tongue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash or flushing of your skin</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy or faint</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heartbeat</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Heart and blood vessel (cardiovascular) problems. </strong>SCEMBLIX may cause heart and blood vessel problems, including heart attack, stroke, blood clots or blockage of your arteries, heart failure, and abnormal heartbeat, which can be serious and may sometimes lead to death. In the majority of cases These heart and blood vessel problems can happen in people with risk factors or a history of these problems, and/or previously treated with other TKI medicines. Your healthcare provider may monitor you for heart and blood vessel problems and treat you as needed during treatment with SCEMBLIX. Tell your healthcare provider or get medical help right away if you get:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain or pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling like your heart is beating too fast or you feel abnormal heartbeats.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling in your ankles or feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight gain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness or weakness on one side of your body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased vision or loss of vision</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble talking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in your arms, legs, back, neck or jaw</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe stomach-area pain</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>The most common side effects of SCEMBLIX include:</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle, bone, or joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nose, throat, or sinus (upper respiratory tract) infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach-area (abdominal) pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased white blood cell counts, platelet counts, and red blood cell counts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased blood calcium corrected levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood pancreas enzyme (lipase and amylase ) levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood fat (cholesterol and triglycerides ) levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood uric acid levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood liver enzyme levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood alkaline phosphatase levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood creatine kinase levels</p><p>&nbsp;</p><p>&nbsp;</p><p>Your healthcare provider may change your dose or temporarily or permanently stop treatment with SCEMBLIX if you have certain side effects.</p><p>&nbsp;</p><p>SCEMBLIX may cause fertility problems in females. This may affect your ability to have a child. Talk to your healthcare provider if this is a concern for you.</p><p>&nbsp;</p><p>These are not all of the possible side effects of SCEMBLIX.</p><p>&nbsp;</p><p>If these side effects become severe, please tell your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP. The expiry date refers to the last day of that month.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Do not store above 25&deg;C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Store in the original package in order to protect from moisture.</p><p>Do not use this medicine if you notice any damage to the packaging or if there are any signs of tampering.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>- </strong>The active substance is asciminib.</p><p>Each 20 mg film coated tablet contains asciminib hydrochloride, equivalent to 20 mg asciminib.</p><p>Each 40 mg film coated tablet contains asciminib hydrochloride, equivalent to 40 mg asciminib.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>20 mg and 40 mg film coated tablets: lactose monohydrate, microcrystalline cellulose (E460i), hydroxypropylcellulose (E463), croscarmellose sodium (E468), polyvinyl alcohol (E1203), titanium dioxide (E171), magnesium stearate, talc (E553b), colloidal silicon dioxide, lecithin (E322), xanthan gum (E415), iron oxide red (E172).</p><p>20 mg film coated tablets only: iron oxide yellow (E172)</p><p>40 mg film coated tablets only: iron oxide black (E172).</p><p>See &ldquo;Scemblix contains lactose and sodium&rdquo; in section 2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Scemblix 20 mg film coated tablets (tablets): pale yellow, round, biconvex tablet with bevelled edges of approximately 6 mm diameter, debossed with company logo on one side and “20” on the other side.
Scemblix 40 mg film coated tablets (tablets): violet white, round, biconvex tablet with bevelled edges of approximately 8 mm diameter, debossed with company logo on one side and “40” on the other side.
Scemblix is supplied in blisters containing 10 film coated tablets.
The following pack sizes are available:
Packs containing 20 or 60 film coated tablets.

Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novartis Europharm Limited</p><p>Vista Building</p><p>Elm Park, Merrion Road</p><p>Dublin 4</p><p>Ireland</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                

e. To report any side effect(s):
•	Saudi Arabia
The National Pharmacovigilance Center (NPC):
o 
o SFDA call center: 19999
o E-mail: npc.drug@sfda.gov.sa
o Website: https://ade.sfda.gov.sa 

Patient Safety Department Novartis Consulting AG - Saudi Arabia:
o Toll Free Number: 8001240078
o Phone: +996112658100 
o Fax: +966112658107
o Email: adverse.events@novartis.com  

•    Other GCC States:
-  Please contact the relevant competent authority.

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو دواء سيمبليكس</strong></p><p dir="RTL">يحتوي دواء سيمبليكس على المادة الفعالة أسيمينيب، والتي تنتمي إلى مجموعة من الأدوية تُسمى مثبطات كيناز البروتين.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>ما هي دواعي استخدام دواء سيمبليكس</strong></p><p dir="RTL">سيمبليكس هو دواء يُصرف بوصفة طبية يُستخدم لعلاج البالغين الذين يعانون من:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابيضاض الدم النقوي المزمن الإيجابي لكروموسوم فيلادلفيا (Ph+ CML)&nbsp; المشخص حديثًا أو الذي تم علاجه مسبقًا في المرحلة المزمنة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ابيضاض الدم النقوي المزمن الإيجابي لكروموسوم فيلادلفيا (Ph+ CML) في المرحلة المزمنة (CP) مع طفرة T315I.</p><p dir="RTL"><strong>آلية عمل دواء سيمبليكس</strong></p><p dir="RTL">في مرض ابيضاض الدم النقوي المزمن الإيجابي لكروموسوم فيلادلفيا في المرحلة المزمنة، ينتج الجسم أعدادًا كبيرة من خلايا الدم البيضاء غير الطبيعية. يمنع دواء سيمبليكس عمل بروتين (BCR::ABL1) تنتجه خلايا الدم البيضاء غير الطبيعية هذه ويوقف انقسامها ونموها.</p><p dir="RTL">إذا كانت لديك أيّة أسئلة حول آلية عمل هذا الدواء أو سبب وصفه لك، فاسأل طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ. موانع استعمال دواء سيمبليكس</strong></p><p dir="RTL">- إذا كانت لديك حساسية تجاه مادة أسيمينيب أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL"><strong>ب. الاحتياطات عند استخدام دواء سيمبليكس</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي لديك قبل تناول دواء سيمبليكس إذا كان أي مما يلي ينطبق عليك:</p><p dir="RTL">- إذا كنت تعاني أو سبق لك أن عانيت من ألم شديد في الجزء العلوي من المعدة يمكن أن يكون بسبب مشكلات في البنكرياس (التهاب البنكرياس).</p><p dir="RTL">- إذا كنت قد أصبت من قبل أو قد تكون مصابًا الآن بعدوى التهاب الكبد ب. وذلك لأن دواء سيمبليكس قد يتسبب في تنشيط التهاب الكبد ب مرة أخرى. سيفحصك طبيبك بعناية بحثًا عن علامات هذه العدوى قبل بدء العلاج.</p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي لديك على الفور بما إذا أصبت بأي مما يلي أثناء تلقي العلاج باستخدام دواء سيمبليكس:</strong></p><p dir="RTL">- إذا عانيت من الوهن، أو نزف تلقائي أو كدمات وعداوى متكررة مصحوبة بعلامات مثل الحمى، أو القشعريرة، أو التهاب الحلق، أو قرحات الفم. يمكن أن تكون هذه علامات على انخفاض نشاط نخاع العظم، مما يؤدي إلى كبت النِّقي (انخفاض في عدد خلايا الدم البيضاء، وخلايا الدم الحمراء، والصفائح الدموية).</p><p dir="RTL">- إذا أظهرت اختبارات الدم أن لديك مستويات عالية من إنزيمين اسمهما الليباز والأميلاز (علامات على تلف البنكرياس، والمعروفة أيضًا باسم سُمية البنكرياس).</p><p dir="RTL">- إذا كنت تعاني من اضطراب في القلب أو اضطراب في نظم القلب، مثل عدم انتظام ضربات القلب أو نشاط كهربائي غير طبيعي للقلب يُسمى إطالة الفاصل الزمني QT والذي يمكن اكتشافه من خلال مخطط كهربية القلب (ECG).</p><p dir="RTL">- إذا أظهرت اختبارات الدم أنك تعاني من انخفاض مستوى البوتاسيوم أو المغنيسيوم (نقص بوتاسيوم الدم أو نقص المغنيسيوم في الدم).</p><p dir="RTL">- إذا كنت تُعالَج بأدوية قد يكون لها تأثير غير مرغوب فيه على وظيفة القلب (تورساد دي بوانت) (انظر &quot;أدوية أخرى ودواء&nbsp;سيمبليكس&quot;).</p><p dir="RTL">- إذا كنت تعاني من صداع، أو دوخة، أو ألم في الصدر، أو ضيق في التنفس (علامات محتملة على الإصابة بارتفاع ضغط&nbsp;الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متابعة حالتك أثناء فترة تلقيك العلاج بدواء سيمبليكس</strong></p><p dir="RTL">سيتابع طبيبك حالتك بانتظام للتحقق من أن العلاج يحقق المفعول المرجو. ستخضع لاختبارات منتظمة بما في ذلك اختبارات الدم أثناء العلاج. ستفحص هذه الاختبارات:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كمية خلايا الدم (خلايا الدم البيضاء، وخلايا الدم الحمراء، والصفائح الدموية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستويات إنزيمات البنكرياس (الأميلاز والليباز).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستويات الكهارل (البوتاسيوم والماغنسيوم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معدل ضربات قلبك وضغط دمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا تعطِ هذا الدواء للأطفال أو المراهقين الذين تقل أعمارهم عن 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. تناول أدوية أخرى، أعشاب أو مكملات غذائية أخرى</strong></p><p dir="RTL">أخبر مقدم الرعاية الصحية المتابع لك بجميع الأدوية التي تتناولها، بما في ذلك الأدوية التي تُصرف بوصفة طبية أو بدون وصفة طبية، والفيتامينات، والمكملات العشبية. قد يؤثر سيمبليكس والأدوية الأخرى على بعضها البعض وقد تسبب أعراض جانبية وقد يؤثر على طريقة عمل سيمبليكس</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>د. تناوُل دواء سيمبليكس مع الطعام والشراب</strong></p><p dir="RTL">لا تتناول هذا الدواء مع الطعام. تناوله بعد تناول الطعام بساعتين وقبل تناول الطعام بساعة واحدة على الأقل. لمزيد من المعلومات، راجع &quot;متى يجب تناول دواء سيمبليكس&quot; في القسم 3.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. الحمل والرضاعة </strong></p><p dir="RTL">إذا كنتِ حاملاً أو تُرضعين طبيعيًا، أو تعتقدين أنكِ قد تكونين حاملاً أو تخططين للإنجاب، فاطلبي الاستشارة من طبيبكِ أو الصيدلي لديكِ قبل تناول هذا الدواء.</p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">قد يضر دواء سيمبليكس بالجنين. إذا كنتِ امرأة قادرة على الحمل، فسيناقش معكِ طبيبكِ المخاطر المحتملة لتناوله أثناء الحمل أو الرضاعة الطبيعية.</p><p dir="RTL">إذا كنتِ امرأة قادرة على الحمل، فقد يُجري طبيبكِ اختبار حمل قبل بدء العلاج بدواء سيمبليكس.</p><p dir="RTL">إذا أصبحتِ حاملاً، أو كنتِ تعتقدين أنكِ قد تكونين حاملاً، بعد بدء العلاج بدواء سيمبليكس، فأخبري طبيبكِ على الفور.</p><p dir="RTL"><u>نصائح لمنع الحمل لدى النساء</u></p><p dir="RTL">إذا كنتِ امرأة قادرة على الحمل، فينبغي عليكِ استخدام وسيلة فعالة لمنع الحمل أثناء تلقي العلاج بدواء سيمبليكس ولمدة 3 أيام على الأقل بعد التوقف عن تناوله لتجنب الحمل. اسألي طبيبكِ عن وسائل منع الحمل الفعالة.&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">من غير المعروف ما إذا كان دواء سيمبليكس ينتقل إلى حليب الثدي. لذلك، يجب عليكِ التوقف عن الإرضاع الطبيعي أثناء تناوله ولمدة 3 أيام على الأقل بعد التوقف عن تناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و. تأثير دواء سيمبليكس على القيادة واستخدام الآلات</strong></p><p dir="RTL">لا يوجد لهذا الدواء أي تأثير أو له تأثير ضئيل على القدرة على القيادة واستخدام الآلات. إذا عانيت من آثار جانبية (مثل الدوخة أو الاضطرابات البصرية) ذات تأثير محتمل على القدرة على القيادة بأمان أو استخدام أيّة أدوات أو آلات بعد تناول هذا الدواء، فيجب عليك الامتناع عن هذه الأنشطة حتى يزول الأثر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ز. معلومات هامة حول بعض مكونات دواء سيمبليكس</strong></p><p dir="RTL"><strong>يحتوي دواء سيمبليكس على اللاكتوز والصوديوم</strong></p><p dir="RTL">إذا أبلغك طبيبك بأنك لا تتحمل بعض السكريات، فاتصل به قبل أخذ هذا المنتج الدوائي.</p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول من الصوديوم (23 ملغ) لكل قرص، أي أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائمًا وفقًا لتوجيهات طبيبك أو الصيدلي لديك. استشر طبيبك أو الصيدلي لديك إذا كانت لديك استفسارات في هذا الصدد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جرعة دواء سيمبليكس التي يجب تناولها&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p dir="RTL">سيخبرك طبيبك بعدد الأقراص التي ينبغي أن تتناولها في اليوم ، وكيفية تناولها.</p><p dir="RTL">ابيضاض الدم النقوي المزمن الإيجابي لكروموسوم فيلادلفيا (Ph+ CML)&nbsp; المشخص حديثًا أو الذي تم علاجه مسبقًا في المرحلة المزمنة</p><p dir="RTL">&nbsp;<u>للجرعة الواحده يوميا</u><u>:</u></p><p dir="RTL">تناول قرصين من سيمبليكس 40 مجم مرة واحدة يوميًا في نفس الوقت تقريبًا.</p><p dir="RTL"><u>للجرعتين يوميا</u><u>:</u></p><p dir="RTL">تناول قرصًا واحدًا من سيمبليكس 40 مجم مرتين يوميًا. تناول قرصًا واحدًا، ثم تناول قرصًا آخر بعد حوالي 12 ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>للمرضى المصابين بـابيضاض الدم النقوي المزمن الإيجابي لكروموسوم فيلادلفيا (</u></strong><strong><u>Ph+ CML</u></strong><strong><u>) في المرحلة المزمنة (</u></strong><strong><u>CP</u></strong><strong><u>) مع طفرة </u></strong><strong><u>T315I</u></strong></p><p dir="RTL">الجرعة الموصى بها هي 5 أقراص من دواء سيمبليكس 40 مجم تؤخذ مرتين يوميًا. تناول 5 أقراص، ثم تناول 5 أقراص أخرى بعد 12 ساعة تقريبًا.</p><p dir="RTL">قد يطلب منك طبيبك تقليل الجرعة أو إيقاف العلاج مؤقتًا أو دائمًا، وذلك يعتمد على استجابتك للعلاج والأعراض الجانبية المحتملة،</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متى يجب تناول دواء سيمبليكس</strong></p><p dir="RTL">تناول دواء سيمبليكس:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد ساعتين على الأقل من تناول أي طعام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثم انتظر ساعة واحدة على الأقل قبل تناول أي طعام مرة أخرى.</p><p dir="RTL">سيساعدك تناول هذا الدواء في نفس الوقت كل يوم على تذكر موعد تناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية تناول دواء سيمبليكس</strong></p><p dir="RTL">ابتلع الأقراص كاملة مع كوب من الماء. لا تكسرها أو تسحقها أو تمضغها لضمان تناول الجرعات المضبوطة.</p><p dir="RTL"><strong>كم مدة تناول دواء سيمبليكس</strong></p><p dir="RTL">استمر في تناول هذا الدواء للفترة التي أخبرك بها طبيبك. هذا علاج طويل الأمد، ربما يستمر لشهور أو سنوات. سيتابع طبيبك حالتك بانتظام للتحقق من أن العلاج يحقق المفعول المرجو.</p><p dir="RTL">إذا كانت لديك أسئلة حول مدة تناول هذا الدواء، فتحدث إلى طبيبك أو الصيدلي لديك.</p><p dir="RTL"><strong>أ. إذا تناولتَ جرعة كبيرة جدًا من دواء سيمبليكس</strong></p><p dir="RTL">&bull; إذا كنت قد تناولت عددًا الأقراص يفوق بكثير الجرعة المحددة لك، أو إذا تناول شخص آخر دواءك عن طريق الخطأ، فاتصل بطبيب على الفور للحصول على المشورة. اعرض عليه العبوة. قد يكون العلاج الطبي ضروريًا.</p><p dir="RTL"><strong>ب. إذا نسيتَ تناول دواء سيمبليكس</strong></p><p dir="RTL">إذا كان يتبقى أقل من 6 ساعات على موعد جرعتك التالية، فتخطى الجرعة الفائتة ثم تناول الجرعة التالية في موعدها.</p><p dir="RTL">إذا كان يتبقى أكثر من 6 ساعات على موعد جرعتك التالية، فتناول الجرعة الفائتة ثم تناول الجرعة التالية في موعدها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. إذا توقفتَ عن تناول دواء سيمبليكس</strong></p><p dir="RTL">لا تتوقف عن تناول هذا الدواء إلا إذا طلب منك طبيبك ذلك.</p><p dir="RTL">إذا كانت لديك أيّة أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي لديك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، قد يسبب هذا الدواء أعراضًا جانبية، ولكن هذه الأعراض لا تصيب الجميع .</p><p dir="RTL"><strong>قد يسبب سيمبليكس أعراضًا جانبية خطيرة، بما في ذلك:</strong></p><ul><li dir="RTL"><strong>انخفاض أعداد خلايا الدم البيضاء.</strong> قد يسبب سيمبليكس انخفاض عدد الصفائح الدموية (قلة الصفيحات)، وانخفاض عدد خلايا الدم البيضاء (قلة العدلات)، وانخفاض عدد خلايا الدم الحمراء (فقر الدم). سيُجري مقدم الرعاية الصحية الخاص بك اختبارات دم للتحقق من عدد خلايا دمك كل أسبوعين خلال الأشهر الثلاثة الأولى من العلاج ثم شهريًا أو حسب الحاجة أثناء العلاج بدواء سيمبليكس. أخبر مقدم الرعاية الصحية على الفور إذا كنت تعاني من نزيف غير متوقع أو سهولة حدوث كدمات، أو دم في البول أو البراز، أو حمى، أو أي علامات للعدوى.</li></ul><p dir="RTL">&nbsp;</p><ul><li dir="RTL"><strong>مشاكل البنكرياس. </strong>قد يزيد سيمبليكس الإنزيمات في دمك التي تُسمى الأميلاز والليباز، والتي قد تكون علامة على التهاب البنكرياس. قد يُجري مقدم الرعاية الصحية اختبارات دم شهريًا أو حسب الحاجة أثناء العلاج بدواء سيمبليكس للتحقق من وجود مشاكل في البنكرياس. أخبر مقدم الرعاية الصحية الخاص بك على الفور إذا شعرت بألم مفاجئ في منطقة المعدة (البطن) أو عدم راحة أو غثيان أو تقيؤ.</li></ul><p dir="RTL">&nbsp;</p><ul><li dir="RTL"><strong>ارتفاع ضغط الدم.</strong> قد يفحص مقدم الرعاية الصحية الخاص بك ضغط دمك ويعالج أي ارتفاع في ضغط الدم أثناء العلاج بدواء سيمبليكس حسب الحاجة. أخبر مقدم الرعاية الصحية إذا أصبت بارتفاع ضغط الدم أو أعراض ارتفاع ضغط الدم، بما في ذلك الارتباك أو الصداع أو الدوار أو ألم الصدر أو ضيق التنفس.</li></ul><p dir="RTL">&nbsp;</p><ul><li dir="RTL"><strong>رد فعل تحسسي.</strong>توقف عن تناول سيمبليكس واطلب المساعدة الطبية على الفور إذا ظهرت عليك أي علامات أو أعراض لرد فعل تحسسي، بما في ذلك:</li></ul><table dir="rtl" border="0" cellpadding="0"><tbody><tr><td><ul><li dir="RTL">صعوبة في التنفس أو البلع</li><li dir="RTL">تورم الوجه أو الشفتين أو اللسان</li><li dir="RTL">طفح جلدي أو احمرار في الجلد</li></ul></td><td><ul><li dir="RTL">الشعور بالدوار أو الإغماء</li><li dir="RTL">الحمى</li><li dir="RTL">سرعة ضربات القلب</li></ul></td></tr></tbody></table><ul><li dir="RTL"><strong>مشاكل في القلب والأوعية الدموية (القلب والأوعية الدموية).</strong> قد يسبب سيمبليكس مشاكل في القلب والأوعية الدموية، بما في ذلك النوبة القلبية، والسكتة الدماغية، والجلطات الدموية أو انسداد الشرايين، وفشل القلب، وضربات القلب غير الطبيعية، والتي قد تكون خطيرة وقد تؤدي أحيانًا إلى الوفاة. في معظم الحالات يمكن أن تحدث هذه المشاكل للأشخاص الذين لديهم عوامل خطر أو لديهم تاريخ مرضي من هذه &nbsp;المشاكل، و/أو سبق علاجهم بأدوية&nbsp; TKI أخرى. قد يراقبك مقدم الرعاية الصحية الخص بك بحثًا عن مشاكل في القلب والأوعية الدموية ويعالجك حسب الحاجة أثناء العلاج بدواء سيمبليكس. أخبر مقدم الرعاية الصحية &nbsp;الخاص بك أو اطلب المساعدة الطبية على الفور إذا كنت تعاني من:</li></ul><table dir="rtl" border="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><ul><li dir="RTL">ضيق في التنفس</li><li dir="RTL">ألم أو ضغط في الصدر</li><li dir="RTL">تشعر بأن قلبك ينبض بسرعة كبيرة أو أنك تشعر بضربات قلب غير طبيعية.</li><li dir="RTL">تورم في الكاحلين أو القدمين</li><li dir="RTL">الدوخة</li><li dir="RTL">زيادة الوزن</li><li dir="RTL">تنميل أو ضعف في جانب واحد من جسمك</li><li dir="RTL">ضعف الرؤية أو فقدان الرؤية</li></ul></td><td style="vertical-align:top"><ul><li dir="RTL">صعوبة في التحدث</li><li dir="RTL">ألم في الذراعين أو الساقين أو الظهر أو الرقبة أو الفك</li><li dir="RTL">الصداع</li><li dir="RTL">ألم شديد في منطقة المعدة</li></ul></td></tr></tbody></table><p dir="RTL"><strong>تشمل الأعراض الجانبية الأكثر شيوعًا لدواء سيمبليكس</strong>:</p><table dir="rtl" border="0" cellpadding="0"><tbody><tr><td><ul><li dir="RTL">&nbsp;آلام العضلات أو العظام أو المفاصل</li><li dir="RTL">&nbsp;طفح جلدي</li><li dir="RTL">&nbsp;ارهاق</li><li dir="RTL">&nbsp;التهاب الأنف أو الحلق أو الجيوب الأنفية (الجهاز التنفسي العلوي)</li><li dir="RTL">&nbsp;صداع</li><li dir="RTL">&nbsp;آلام منطقة المعدة (البطن)الإسهال</li></ul></td><td><ul><li dir="RTL">&nbsp;انخفاض عدد خلايا الدم البيضاء، وعدد الصفائح الدموية، وعدد خلايا الدم الحمراء</li><li dir="RTL">&nbsp;انخفاض مستويات الكالسيوم المصححة في الدم</li><li dir="RTL">&nbsp;ارتفاع مستويات إنزيمات البنكرياس في الدم (الليباز والأميليز)</li><li dir="RTL">&nbsp;ارتفاع مستويات الدهون في الدم (الكوليسترول والدهون الثلاثية)</li><li dir="RTL">&nbsp;ارتفاع مستويات حمض اليوريك في الدم</li><li dir="RTL">&nbsp;ارتفاع مستويات إنزيمات الكبد في الدم</li><li dir="RTL">&nbsp;ارتفاع مستويات الفوسفاتيز القلوية في الدم</li><li dir="RTL">&nbsp;ارتفاع مستويات كيناز الكرياتين في الدم</li></ul></td></tr></tbody></table><p dir="RTL">قد يغير مقدم الرعاية الصحية جرعتك أو يوقف العلاج بدواء سيمبليكس مؤقتًا أو دائمًا إذا كنت تعاني من أعراض جانبية معينة.</p><p dir="RTL">قد يسبب سيمبليكس مشاكل في الخصوبة لدى الإناث. وقد يؤثر ذلك على القدرة على الإنجاب. تحدثي إلى مقدم الرعاية الصحية الخاص بك إذا كان هذا الأمر &nbsp;يقلقك.&nbsp;</p><p dir="RTL">هذه ليست جميع الأعراض الجانبية المحتملة لدواء سيمبليكس.</p><p dir="RTL">إذا أصبحت هذه الأعراض الجانبية شديدة أو خطيرة، فيُرجى إخبار طبيبك على الفور.</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا تعرضت لأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي. يشمل هذا أيّ أعراض جانبية محتملة غير مذكورة في هذه النشرة. بإبلاغك عن الأعراض الجانبية، فإنّك تساعد في توفير المزيد من المعلومات حول مدى سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى الأطفال ومتناولهم.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء صلاحيته المدوَّن على الشريط والعلبة الكرتونية بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.&nbsp;</p><p dir="RTL">لا تخزنه في درجة حرارة أعلى من 25 درجة مئوية.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">يُحفظ في العبوة الأصلية لحمايته من الرطوبة.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي تلف في العبوة أو إذا كانت هناك أيّة علامات على العبث.</p><p dir="RTL">لا تتخلص من أيّة أدوية عبر مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي لديك عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-<strong> </strong>المادة الفعالة هي الأسيمينيب.</p><p dir="RTL">يحتوي كل قرص مغلف 20 ملغ على هيدروكلوريد أسيمينيب، أي ما يعادل 20 ملغ من الأسيمينيب.</p><p dir="RTL">يحتوي كل قرص مغلف 40 ملغ على هيدروكلوريد أسيمينيب، أي ما يعادل 40 ملغ من الأسيمينيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">أقراص مغلفة 20 ملغ و40 ملغ: أحادي هيدرات اللاكتوز، سليلوز بلوري مكروي (E460i)، هيدروكسي بروبيل سليلوز (E463)، كروس كارميلوز الصوديوم (E468)، كحول بولي فينيل (E1203)، ثاني أكسيد التيتانيوم (E171)، ستيارات المغنيسيوم، التلك (E553b)، ثاني أكسيد السيليكون الغرواني، ليسيثين (E322)، صمغ الزانثان (E415)، أكسيد الحديد الأحمر (E172).</p><p dir="RTL">أقراص مغلفة 20 ملغ فقط: أكسيد الحديد الأصفر (E172)</p><p dir="RTL">أقراص مغلفة 40 ملغ فقط: أكسيد الحديد الأسود (E172).</p><p dir="RTL">انظر &quot;يحتوي سيمبليكس على اللاكتوز والصوديوم&quot; في القسم 2</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص سيمبليكس المغلفة 20 ملغ (أقراص): قرص أصفر باهت، مستدير، محدب الوجهين بحواف مشطوفة يبلغ قُطرها حوالي 6 مم، منقوش عليها شعار الشركة على أحد الجانبين والرقم &quot;20&quot; على الجانب الآخر.</p><p dir="RTL">أقراص سيمبليكس المغلفة 40 ملغ (الأقراص): قرص أبيض بنفسجي، مستدير، محدب الوجهين بحواف مشطوفة يبلغ قُطرها 8 مم تقريبًا، منقوش عليها شعار الشركة على أحد الجانبين والرقم &quot;40&quot; على الجانب الآخر.</p><p dir="RTL">يتم توفير دواء سيمبليكس في أشرطة تحتوي على 10 أقراص مغلفة.</p><p dir="RTL">تتوفر أحجام العبوات التالية:</p><p dir="RTL">عبوات تحتوي على 20 أو 60 قرصًا مغلفًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تكون جميع أحجام العبوات مطروحة في السوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس يوروفارم المحدودة، أيرلندا</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ‌

هـ. للإبلاغ عن الأعراض الجانبية:
•	المملكة العربية السعودية
          المركز الوطني للتَّيقظ والسَّلامة الدَّوائية (NPC):
	مركز اتصال الهيئة السعودية العامة للغذاء والدَّواء: 19999
	البريد الإلكتروني: npc.drug@sfda.gov.sa
	الموقع الإلكتروني: https://ade.sfda.gov.sa 

-	شركة نوفارتس - السعودية - قسم سلامة المرضى:
	الهاتف المجاني: 8001240078
	الهاتف: 966112658100+ 
	الفاكس: 966112658107+
	البريد الإلكتروني: adverse.events@novartis.com  

•	دول مجلس التَّعاون الخليجي الأخرى:
يُرجى الاتصال بسلطات الاختصاص المعنية.

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Scemblix 20 mg film coated tablets
Scemblix 40 mg film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Scemblix 20 mg film coated tablets

Each film coated tablet contains 21.62 mg asciminib hydrochloride, equivalent to 20 mg asciminib.

Excipient with known effect
Each film coated tablet contains 43 mg lactose monohydrate.

Scemblix 40 mg film coated tablets

Each film coated tablet contains 43.24 mg asciminib hydrochloride, equivalent to 40 mg asciminib.

Excipient with known effect
Each film coated tablet contains 86 mg lactose monohydrate.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet (tablet).

Scemblix 20 mg film coated tablets

Pale yellow, round, biconvex film coated tablets with bevelled edges of approximately 6 mm diameter, debossed with company logo on one side and “20” on the other side.

Scemblix 40 mg film coated tablets

Violet white, round, biconvex film coated tablets with bevelled edges of approximately 8 mm diameter, debossed with company logo on one side and “40” on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SCEMBLIX is indicated for the treatment of adult patients with:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).</p><p>This indication is approved under accelerated approval based on major molecular response rate (see section 5). Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Previously treated Ph+ CML in CP.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ph+ CML in CP with the T315I mutation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Recommended Dosage in Patients with Newly Diagnosed or Previously Treated Ph+ CML-CP The recommended dose of SCEMBLIX is 80 mg taken orally once daily at approximately the same time each day or 40 mg orally twice daily at approximately 12-hour intervals. The recommended dose of SCEMBLIX is taken orally without food. Avoid food consumption for at least 2 hours before and 1 hour after taking SCEMBLIX (see section 5.1).</p><p>Continue treatment with SCEMBLIX as long as clinical benefit is observed or until unacceptable toxicity occurs.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended Dosage in Patients with Ph+ CML-CP with the T315I Mutation</p><p>The recommended dose of SCEMBLIX is 200 mg taken orally twice daily at approximately 12-hour intervals. The recommended dose of SCEMBLIX is taken orally without food. Avoid food consumption for at least 2 hours before and 1 hour after taking SCEMBLIX (see section 5.1).</p><p>&nbsp;</p><p><u>Missed dose</u></p><p>Once Daily Dosage Regimen: If a SCEMBLIX dose is missed by more than approximately 12 hours, skip the dose and take the next dose as scheduled.</p><p>Twice Daily Dosage Regimens: If a SCEMBLIX dose is missed by more than approximately 6 hours, skip the dose and take the next dose as scheduled.</p><p>&nbsp;</p><p><u>Dosage modifications</u></p><p><u>Dosage Modifications for Patients with Newly Diagnosed or Previously Treated Ph+ CML-CP</u> For the management of adverse reactions, reduce the SCEMBLIX dose as described in Table 1. <u>Dosage Modifications for Patients with Ph+ CML-CP with the T315I Mutation</u></p><p>For the management of adverse reactions, reduce the SCEMBLIX dose as described in Table 1.</p><p>&nbsp;</p><p>Table 1: Recommended Dosage Reductions for SCEMBLIX for Adverse Reactions</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Dosage </strong><strong>Reduction</strong></p></td><td style="vertical-align:top"><p>Dosage for Patients with newly diagnosed or previously treated Ph+ CML-CP</p></td><td style="vertical-align:top"><p><strong>Dosage for Patients with Ph+ CML-CP with the T315I Mutation</strong></p></td></tr><tr><td style="vertical-align:top"><p>First</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40 mg once daily OR</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20 mg twice daily</p></td><td style="vertical-align:top"><p>160 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Subsequent Reduction</p></td><td style="vertical-align:top"><p>Permanently discontinue SCEMBLIX in patients unable to tolerate 40 mg once daily OR 20 mg twice daily.</p></td><td style="vertical-align:top"><p>Permanently discontinue SCEMBLIX in patients unable to tolerate 160 mg twice daily.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>The recommended dosage modifications for the management of selected adverse reactions are shown in Table 2.</p><p>&nbsp;</p><p>Table 2: SCEMBLIX Dosage Modification for the Management of Adverse Reactions</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse</strong><strong> Reaction</strong></p></td><td style="vertical-align:top"><p><strong>Dosage Modification</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Thrombocytopenia</strong><strong> </strong><strong>and/or</strong><strong> </strong><strong>neutropenia</strong><strong> </strong><em>(see</em><em> </em><em>section</em><em> </em><em>4.4)</em></p></td></tr><tr><td style="vertical-align:top"><p>ANC less than 1.0 x 10<sup>9</sup>/L and/or PLT less than 50 x 10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p>Withhold SCEMBLIX until resolved to ANC greater than or equal to 1 x 10<sup>9</sup>/L and/or PLT greater than or equal to 50 x 10<sup>9</sup>/L.</p><p>If resolved:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Within 2 weeks: resume SCEMBLIX at starting dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After more than 2 weeks: resume SCEMBLIX at reduced dose.</p><p>For recurrent severe thrombocytopenia and/or neutropenia, withhold SCEMBLIX until resolved to ANC greater than or equal to 1 x 10<sup>9</sup>/L and PLT greater than or equal to 50 x 10<sup>9</sup>/L, then resume at reduced dose.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Asymptomatic amylase and/or lipase elevation </strong><em>(see section 4.4)</em></p></td></tr><tr><td style="vertical-align:top"><p>Elevation greater than 2.0 x ULN</p></td><td style="vertical-align:top"><p>Withhold SCEMBLIX until resolved to less than 1.5 x ULN. If resolved:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume SCEMBLIX at reduced dose. If events reoccur at reduced dose, permanently discontinue SCEMBLIX.</p><p>If not resolved:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue SCEMBLIX. Perform diagnostic tests to exclude pancreatitis.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Non-hematologic</strong><strong> </strong><strong>adverse</strong><strong> </strong><strong>reactions</strong><strong> </strong><strong><em>(see</em></strong><strong><em> </em></strong><strong><em>section</em></strong><strong><em> </em></strong><strong><em>4.4)</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Grade 3<sup>a</sup> or higher</p></td><td style="vertical-align:top"><p>Withhold SCEMBLIX until recovery to Grade 1 or less. If resolved:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume SCEMBLIX at reduced dose.</p><p>If not resolved:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue SCEMBLIX.</p></td></tr></tbody></table><p>&nbsp;</p><p>Abbreviations: ANC, absolute neutrophil count; PLT, platelets; ULN, upper limit of normal.</p><p><sup>a</sup> Based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:467.7pt;height:26.55pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p><em><u>Special populations</u> </em></p><p><em>Elderly</em></p><p>Among the 556 patients receiving SCEMBLIX in the ASC4FIRST, ASCEMBL and X2101 studies, 130 (23%) were 65 years of age and older and 31 (6%) were 75 years of age and older.</p><p>Overall, no differences in safety or efficacy of SCEMBLIX were observed between patients 65 years of age and older compared to younger patients.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p><em>&nbsp;</em></p><p>No dose adjustment is required for patients with mild to severe renal impairment (estimated glomerular filtration rate [eGFR] 15 to 89 mL/min/1.73 m2) and not requiring dialysis receiving SCEMBLIX (see section 5.2)</p><p><em>Hepatic impairment</em></p><p><em>&nbsp;</em></p><p>No dose adjustment is required for patients with mild [total bilirubin &le; upper limit of normal (ULN) and aspartate aminotransferase (AST) &gt; ULN or total bilirubin &gt; 1 to 1.5 times ULN and any AST] to severe hepatic impairment (total bilirubin &gt; 3 times ULN and any AST) receiving SCEMBLIX (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>The safety and efficacy of Scemblix in paediatric patients aged below 18 years have not been established. <u>Method of administration</u></p><p>Scemblix is for oral use. The film-coated tablets should not be broken, crushed or chewed.</p><p>&nbsp;</p><p>The tablets should be taken orally without food. Food consumption should be avoided for at least 2 hours before and 1 hour after taking asciminib (see section 5.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Myelosuppression</u></p><p>Thrombocytopenia, neutropenia, and anemia have occurred in patients receiving SCEMBLIX. Thrombocytopenia occurred in 156 of 556 (28%) patients receiving SCEMBLIX, with Grade 3 or 4 thrombocytopenia reported in 39 (7%) and 53 (10%) of patients, respectively. Among the patients with Grade 3 or 4 thrombocytopenia, median time to first occurrence of events was 6 weeks (range, 0.1 to 64 weeks). SCEMBLIX was permanently discontinued in 11 (2%) patients, while it was temporarily withheld in 70 (13%) patients due to thrombocytopenia.</p><p>Neutropenia occurred in 120 (22%) patients receiving SCEMBLIX, with Grade 3 and 4 neutropenia reported in 41 (7%) and 35 (6%) patients, respectively. Among the patients with Grade 3 or 4 neutropenia, median time to first occurrence of events was 7 weeks (range, 0.1 to 180 weeks). SCEMBLIX was permanently discontinued in 7 (1.3%) patients, while it was temporarily withheld in 52 (9%) patients due to neutropenia.</p><p>Anemia occurred in 70 (13%) patients receiving SCEMBLIX, with Grade 3 anemia occurring in 22 (4%) patients. Among the patients with Grade 3 or 4 anemia, median time to first occurrence of events was 22 weeks (range, 0.1 to 207 weeks). SCEMBLIX was temporarily withheld in 2 (0.4%) patients due to anemia (see section 4.8).</p><p>Perform complete blood counts every two weeks for the first 3 months of treatment and monthly thereafter or as clinically indicated. Monitor patients for signs and symptoms of myelosuppression<em>.</em></p><p>Based on the severity of thrombocytopenia and/or neutropenia, reduce dose, temporarily withhold, or permanently discontinue SCEMBLIX <em>(see section 4.2)</em></p><p><em>&nbsp;</em></p><p><u>Pancreatic toxicity</u></p><p>Pancreatitis occurred in 11 of 556 (2%) patients receiving SCEMBLIX, with Grade 3 pancreatitis occurring in 6 (1.1%) patients. SCEMBLIX was permanently discontinued in three (0.5%) patients, while it was temporarily withheld in 6 (1.1%) patients due to pancreatitis. Elevation of serum lipase and amylase occurred in 107 of 556 (19%) patients receiving SCEMBLIX, with Grade 3 and Grade 4 pancreatic enzyme elevations occurring in 41 (7%) and 11 (2%) patients, respectively. SCEMBLIX was permanently discontinued in 11 (2%) patients due to the elevation of serum lipase and amylase <em>(see section 4.8)</em></p><p>Assess serum lipase and amylase levels monthly during treatment with SCEMBLIX, or as clinically indicated. Monitor patients for signs and symptoms of pancreatic toxicity. Perform more frequent monitoring in patients with a history of pancreatitis. If lipase and amylase elevation are accompanied by abdominal symptoms, temporarily withhold SCEMBLIX and consider appropriate diagnostic tests to exclude pancreatitis (see section 4.2).</p><p>Based on the severity of lipase and amylase elevation, reduce dose, temporarily withhold, or permanently discontinue SCEMBLIX (see section 4.2).</p><p>&nbsp;</p><p><u>Hypertension</u></p><p>Hypertension occurred in 90 of 556 (16%) patients receiving SCEMBLIX, with Grade 3 or 4 hypertension reported in 49 (9%) and 1 (0.2%) patients, respectively. Among the patients with Grade 3 or 4 hypertension, median time to first occurrence was 32 weeks (range, 0.1 to 365 weeks). SCEMBLIX was temporarily withheld in 5 (0.9%) patients due to hypertension (see section 4.8)</p><p>Monitor and manage hypertension using standard antihypertensive therapy during treatment with SCEMBLIX as clinically indicated; for Grade 3 or higher hypertension, temporarily withhold, reduce dose, or permanently discontinue SCEMBLIX depending on persistence of hypertension (see section 4.2)</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>Hypersensitivity occurred in 168 of 556 (30%) patients receiving SCEMBLIX, with Grade 3 or 4 hypersensitivity reported in 7 (1.3%) patients <em>(see section 4.8). </em>Reactions included rash, edema, and bronchospasm. Monitor patients for signs and symptoms of hypersensitivity and initiate appropriate treatment as clinically indicated; for Grade 3 or higher hypersensitivity, temporarily withhold, reduce dose, or permanently discontinue SCEMBLIX depending on persistence of hypersensitivity (see section 4.2)</p><p>&nbsp;</p><p><u>Cardiovascular Toxicity</u></p><p>&nbsp;</p><p>Cardiovascular toxicity (including ischemic cardiac and CNS conditions, arterial thrombotic and embolic conditions) and</p><p>cardiac failure occurred in 60 (11%) and in 13 (2.3%) of 556 patients receiving SCEMBLIX, respectively <em>(see section 4.8).</em>. Grade 3 cardiovascular toxicity was reported in 14 (2.5%) patients, while Grade 3 cardiac failure was observed in 5 (0.9%) patients. Grade 4 cardiovascular toxicity occurred in 4 (0.7%) patients, with fatalities occurring in 4 (0.7%) patients. Grade 4 cardiac failure was reported in 1 (0.2%) patient with fatality occurring in 1 (0.2%) patient. Permanent discontinuation of SCEMBLIX occurred in 4 (0.7%) patients due to cardiovascular toxicity and in 1 (0.2%) patient due to cardiac failure, respectively. In the majority of patients, cardiovascular toxicity occurred in patients with preexisting cardiovascular conditions or risk factors, and/or prior exposure to multiple TKIs.</p><p>Arrhythmia, including QTc prolongation, occurred in 35 of 556 (6%) patients receiving SCEMBLIX, with Grade 3 or 4 arrhythmia reported in 10 (1.8%) and 2 (0.4%) patients, respectively. QTc prolongation occurred in 5 of 556 (0.9%) patients receiving SCEMBLIX, with Grade 3 QTc prolongation reported in 2 (0.4%) patients <em>(see section 4.8)</em></p><p>Monitor patients with history of cardiovascular risk factors for cardiovascular signs and symptoms. Initiate appropriate treatment as clinically indicated; for Grade 3 or higher cardiovascular toxicity, temporarily withhold, reduce dose, or permanently discontinue SCEMBLIX depending on persistence of cardiovascular toxicity (see section 4.2)</p><p>&nbsp;</p><p><u>Embryo-Fetal Toxicity</u></p><p>Based on findings from animal studies and its mechanism of action, SCEMBLIX can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of asciminib to pregnant rats and rabbits during the period organogenesis caused adverse developmental outcomes, including embryo-fetal mortality and malformations at maternal exposures (AUC) equivalent to or less than those in patients at the recommended doses. Advise pregnant women and females of reproductive potential of the potential risk to a fetus if SCEMBLIX is used during pregnancy or if the patient becomes pregnant while taking SCEMBLIX. Verify the pregnancy status of females of reproductive potential prior to starting treatment with SCEMBLIX. Females of reproductive potential should use effective contraception during treatment with SCEMBLIX and for 1 week after the last dose (see section 4.6)</p><p><strong><u>Lactose</u></strong></p><p>Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p><strong><u>Sodium</u></strong></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effect of Other Drugs on SCEMBLIX</p><p><u>Strong CYP3A4 Inhibitors</u></p><p>Asciminib is a CYP3A4 substrate. Concomitant use of SCEMBLIX with a strong CYP3A4 inhibitor increases both the asciminib C<sub>max </sub>and AUC, which may increase the risk of adverse reactions <em>(see section 5.2)</em>. Closely monitor for adverse reactions in patients treated with SCEMBLIX at 200 mg twice daily with concomitant use of strong CYP3A4 inhibitors.</p><p><u>Itraconazole Oral Solution Containing Hydroxypropyl-&beta;-cyclodextrin</u></p><p>Concomitant use of SCEMBLIX with itraconazole oral solution containing hydroxypropyl-&beta;-cyclodextrin decreases asciminib C<sub>max</sub> and AUC, which may reduce SCEMBLIX efficacy <em>(see section 5.2)</em>. Avoid coadministration of SCEMBLIX at all recommended doses with itraconazole oral solution containing hydroxypropyl-&beta;-cyclodextrin.</p><p>&nbsp;</p><p>Effect of SCEMBLIX on Other Drugs</p><p><u>Certain CYP3A4 Substrates</u></p><p>Asciminib is a CYP3A4 inhibitor. Concomitant use of SCEMBLIX increases the C<sub>max</sub> and AUC of CYP3A4 substrates, which may increase the risk of adverse reactions of these substrates <em>(see section 5.2)</em>.</p><p>Closely monitor for adverse reactions in patients treated with SCEMBLIX at 80 mg total daily dose with concomitant use of certain CYP3A4 substrates, where minimal concentration changes may lead to serious adverse reactions. Avoid coadministration of SCEMBLIX at 200 mg twice daily with certain CYP3A4 substrates, where minimal concentration changes may lead to serious adverse reactions.</p><p><u>CYP2C9 Substrates </u></p><p>Asciminib is a CYP2C9 inhibitor. Concomitant use of SCEMBLIX increases the C<sub>max</sub> and AUC of CYP2C9 substrates, which may increase the risk of adverse reactions of these substrates <em>(see section 5.2)</em>.</p><p>Avoid coadministration of SCEMBLIX at 80 mg total daily dose with certain CYP2C9 substrates, where minimal concentration changes may lead to serious adverse reactions. If coadministration is unavoidable, reduce the CYP2C9 substrate dosage as recommended in its prescribing information.</p><p>Avoid coadministration of SCEMBLIX at 200 mg twice daily with sensitive CYP2C9 substrates and certain CYP2C9 substrates, where minimal concentration changes may lead to serious adverse reactions. If coadministration is unavoidable, consider alternative therapy with a non-CYP2C9 substrate.</p><p><u>Certain P-gp Substrates</u></p><p>Asciminib is a P-gp inhibitor. Concomitant use of SCEMBLIX increases the plasma concentrations of P-gp substrates, which may increase the risk of adverse reactions of these substrates <em>(see section 5.2)</em>.</p><p>Closely monitor for adverse reactions in patients treated with SCEMBLIX at all recommended doses with concomitant use of P-gp substrates, where minimal concentration changes may lead to serious toxicities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Pregnancy</p><p>&nbsp;</p><p><u>Risk Summary </u></p><p>Based on findings from animal studies and the mechanism of action, SCEMBLIX can cause embryo-fetal harm when administered to a pregnant woman (see section 5.1). There are no available data on SCEMBLIX use in pregnant women to evaluate a drug associated risk.</p><p>&nbsp;</p><p>Animal reproduction studies in pregnant rats and rabbits demonstrated that oral administration of asciminib during organogenesis induced structural abnormalities, embryo-fetal mortality, and alterations to growth (see Data).</p><p>&nbsp;</p><p>Advise pregnant women and females of reproductive potential of the potential risk to a fetus.</p><p>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</p><p>&nbsp;</p><p><u>Data </u></p><p><em>Animal Data</em></p><p>&nbsp;</p><p>In embryo-fetal development studies, pregnant animals received oral doses of asciminib at 25, 150, and 600 mg/kg/day in rats and at 15, 50, and 300 mg/kg/day in rabbits during the period of organogenesis.</p><p>&nbsp;</p><p>In rats, maternal toxicity at the asciminib dose of 600 mg/kg/day resulted in the early termination of the dose group; a complete embryo-fetal examination was not conducted for this group. Adverse embryo-fetal findings were observed at 25 and 150 mg/kg; these doses did not cause maternal toxicities. Increases in fetal weights at 25 and 150 mg/kg/day were observed, which may be related to increased ossification (i.e., increased rate of development). Malformations were evident at 150 mg/kg and included cleft palate, anasarca (edema), and cardiac abnormalities. Additional fetal findings included urinary tract and skeletal variations, observed primarily at 150 mg/kg/day. At the dose of 25 mg/kg/day, the area under the curve (AUC) exposures were equivalent to or below those achieved in patients at the 40 mg twice daily or 80 mg once daily doses, respectively. At the dose of 25 mg/kg/day, the AUC exposures were below those achieved in patients at the 200 mg twice daily dose.</p><p>&nbsp;</p><p>In rabbits, maternal toxicities at the asciminib dose of 300 mg/kg/day resulted in the early termination of the dose group; a complete embryo-fetal examination was not conducted for this group. Adverse embryo-fetal findings were observed at 50 mg/kg; this dose did not cause maternal toxicities. Findings at the 50 mg/kg dose included increases in early resorptions and post-implantation loss, decreases in the number of live fetuses, and cardiac malformations. At the dose of 50 mg/kg/day, the AUC exposures were 4-fold those achieved in patients at the 40 mg twice daily or 80 mg once daily doses. At the dose of 50 mg/kg/day, the AUC exposures were below those achieved in patients at the 200 mg twice daily dose.</p><p>Lactation</p><p>&nbsp;</p><p><u>Risk Summary </u></p><p>There are no data on the presence of asciminib or its metabolites in human milk, the effects on the breastfed child, or milk production.</p><p>Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with SCEMBLIX and for 1 week after the last dose.</p><p>&nbsp;</p><p>&nbsp;</p><p>Females and Males of Reproductive Potential</p><p>Based on findings from animal studies, SCEMBLIX can cause embryo-fetal harm when administered to a pregnant woman (see section 4.6).</p><p>&nbsp;</p><p><u>Pregnancy Testing</u></p><p>Verify the pregnancy status of females of reproductive potential prior to starting treatment with SCEMBLIX.</p><p>&nbsp;</p><p><u>Contraception </u></p><p>Females</p><p>Females of reproductive potential should use effective contraception during treatment with SCEMBLIX and for 1 week after the last dose.</p><p>&nbsp;</p><p><u>Infertility </u></p><p>Based on findings in animals, SCEMBLIX may impair fertility in females of reproductive potential (see section 5.3). The reversibility of the effect on fertility is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Asciminib has no or negligible influence on the ability to drive and use machines. However, it is recommended that patients experiencing dizziness, fatigue or other undesirable effects (see section&nbsp;4.8) with a potential impact on the ability to drive or use machines safely should refrain from these activities as long as the undesirable effects persist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following clinically significant adverse reactions can occur with SCEMBLIX and are discussed in greater detail in other sections of the labeling:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myelosuppression <em>(see section 4.4)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pancreatic Toxicity <em>(see section 4.4)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension <em>(see section 4.4)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity <em>(see section 4.4)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiovascular Toxicity <em>(see section 4.4)</em></p><p><em>&nbsp;</em></p><p>Summary of the safety profile Clinical Trials Experience</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical</p><p>trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to SCEMBLIX at 10 mg to 200 mg orally twice daily (between 0.25 to 5 times the recommended dosage for the 80 mg daily dosage and between 0.05 times and up to the recommended dosage for the 200 mg twice daily dosage) in 556 patients enrolled in one of three clinical trials, including patients with Ph+ CML in CP receiving SCEMBLIX as monotherapy: study CABL001J12301 (ASC4FIRST), study CABL001A2301 (ASCEMBL) and study CABL001X2101 (<em>see section 5).</em></p><p>Among the 556 patients receiving SCEMBLIX, the median duration of exposure to SCEMBLIX was 83 weeks (range, 0.1 to 439 weeks), with 79% of patients exposed for at least 48 weeks and 42% of patients exposed for at least 96 weeks, respectively.</p><p>The most common (&ge; 20%) adverse reactions in patients who received SCEMBLIX were musculoskeletal pain, rash, fatigue, upper respiratory tract infection, headache, abdominal pain, and diarrhea.</p><p><u>Adverse Reactions in Patients with Newly Diagnosed Ph+ CML-CP</u></p><p>The ASC4FIRST clinical trial randomized 405 patients with newly diagnosed Ph+ CML-CP to receive SCEMBLIX 80 mg once daily or investigator selected tyrosine kinase inhibitors (IS-TKIs). IS-TKIs included imatinib (400 mg once daily), nilotinib (300 mg twice daily), dasatinib (100 mg once daily), or bosutinib (400 mg once daily) <em>(See section 5). </em>The safety population (received at least 1 dose of SCEMBLIX) included 200 patients with newly diagnosed Ph+ CML- CP. Among patients who received SCEMBLIX, 90% were exposed for 48 weeks or longer <em>(See section 5).</em></p><p>Serious adverse reactions occurred in 11% of patients who received SCEMBLIX. Serious adverse reactions in &ge; 1% included pancreatitis (1%), and musculoskeletal pain (1%).</p><p>Permanent discontinuation due to an adverse reaction occurred in 4.5% of patients receiving SCEMBLIX. Adverse reactions which resulted in permanent discontinuation of SCEMBLIX in &ge; 1% of patients included pancreatic enzymes increased (1.5%) and thrombocytopenia (1%).</p><p>Dosage interruptions of SCEMBLIX due to an adverse reaction occurred in 30% of patients. Adverse reactions which required dosage interruption in &gt; 5% of patients included thrombocytopenia (13%) and neutropenia (10%).</p><p>Dose reductions of SCEMBLIX due to an adverse reaction occurred in 6% of patients. Adverse reactions which required dose reductions in &gt; 1% of patients included thrombocytopenia (2.5%) and neutropenia (1.5%).</p><p>The most common (&ge; 20%) adverse reaction in patients who received SCEMBLIX was musculoskeletal pain. The most common select laboratory abnormalities that worsened from baseline in &ge; 20% of patients who received</p><p>SCEMBLIX were lymphocyte count decreased, leukocyte count decreased, platelet count decreased, neutrophil count decreased, calcium corrected decreased, lipase increased, cholesterol increased, uric acid increased, alanine aminotransferase (ALT) increased, alkaline phosphatase (ALP) increased, hemoglobin decreased, and triglycerides increased.</p><p>Table 3 summarizes the adverse reactions in ASC4FIRST.</p><p>&nbsp;</p><p>Table 3: Adverse Reactions (&ge; 10%) in Patients with Newly Diagnosed Ph+ CML in CP, Who Received SCEMBLIX in ASC4FIRST</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>SCEMBLIX </strong><strong>N = 200</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>IS-TKIs </strong><strong>N = 201</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4</strong></p><p><strong>%</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain<sup>a</sup></p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash<sup>b</sup></p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>c</sup></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Gastrointestinal</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea<sup>d</sup></p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain<sup>e</sup></p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection<sup>f</sup></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dyslipidemia<sup>g</sup></p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache<sup>h</sup></p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Abbreviations: Ph+ CML in CP, Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP); IS-TKIs, investigator selected tyrosine kinase inhibitors.</p><p><sup>a</sup>Musculoskeletal pain includes: musculoskeletal pain, myalgia, pain in extremity, back pain, non-cardiac chest pain, bone pain, neck pain, musculoskeletal stiffness, musculoskeletal discomfort, musculoskeletal chest pain, arthritis, and spinal pain.</p><p><sup>b</sup>Rash includes: rash, rash maculo-papular, rash pustular, rash macular, dermatitis exfoliative, drug eruption, dermatitis acneiform, eczema, rash pruritic and rash vesicular.</p><p><sup>c</sup>Fatigue includes: fatigue and asthenia.</p><p><sup>d</sup>Diarrhea includes: diarrhea, colitis and enteritis.</p><p><sup>e</sup>Abdominal pain includes: abdominal pain, abdominal pain upper, abdominal discomfort, abdominal pain lower and gastrointestinal pain.</p><p><sup>f</sup>Upper respiratory tract infection includes: upper respiratory tract infection, nasopharyngitis, pharyngitis, rhinitis and respiratory tract infection.</p><p><sup>g</sup>Dyslipidemia includes: dyslipidemia, hypertriglyceridemia, blood cholesterol increased, hypercholesterolemia, hyperlipidemia and blood triglycerides increased.</p><p><sup>h</sup>Headache contains: headache and migraine.</p></td></tr></tbody></table><p>Clinically relevant adverse reactions in &lt; 10% of patients treated with SCEMBLIX in ASC4FIRST included: arthralgia, constipation, nausea, hypertension, cough, pruritus, dry eye, pyrexia, vomiting, dizziness, edema, lower respiratory tract infection, decreased appetite, hypothyroidism, urticaria, arrhythmia, influenza, neuropathy peripheral, hemorrhage, urinary tract infection, pneumonia, dyspnea, pancreatitis, vision blurred, febrile neutropenia, and palpitations.</p><p>Table 4 summarizes the laboratory abnormalities in ASC4FIRST.</p><p>&nbsp;</p><p>Table 4: Select Laboratory Abnormalities (&ge; 20%) That Worsened From Baseline in Patients with Newly Diagnosed Ph+ CML in CP, Who Received SCEMBLIX in ASC4FIRST</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>SCEMBLIX<sup>a</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>IS-TKIs<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Laboratory Abnormality</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4</strong></p><p><strong>%</strong></p></td></tr><tr><td style="vertical-align:top"><p>Lymphocyte count decreased</p></td><td style="vertical-align:top"><p>71</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>82</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>Leukocyte count decreased</p></td><td style="vertical-align:top"><p>54</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>66</p></td><td style="vertical-align:top"><p>13</p></td></tr><tr><td style="vertical-align:top"><p>Platelet count decreased</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>55</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>Neutrophil count decreased</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>62</p></td><td style="vertical-align:top"><p>20</p></td></tr><tr><td style="vertical-align:top"><p>Hemoglobin decreased</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>49</p></td><td style="vertical-align:top"><p>4.5</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Biochemical parameters</strong></p></td></tr><tr><td style="vertical-align:top"><p>Calcium corrected decreased</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>71</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Lipase increased</p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>Cholesterol increased</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Uric acid increased<sup>b</sup></p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase (ALT) increased</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>27</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>1.5</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>40</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Alkaline phosphatase (ALP) increase</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Triglycerides increased</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup>The denominator used to calculate the rate for SCEMBLIX and IS TKIs varied from 198 to 200 and 201, respectively, based on the number of patients with a baseline value and at least one post-treatment value.</p><p><sup>b</sup>Worst post-baseline laboratory abnormalities based on normal ranges. CTCAE version 5.0</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Adverse Reactions in Patients with Ph+ CML-CP, Previously Treated with Two or More TKIs</u></p><p>The clinical trial randomized and treated 232 patients with Ph+ CML-CP, previously treated with two or more TKIs to receive SCEMBLIX 40 mg twice daily or bosutinib 500 mg once daily (ASCEMBL) <em>(see section 5.1) </em>The safety population (received at least 1 dose of SCEMBLIX) included 156 patients with Ph+ CML-CP, previously treated with two or more TKIs. Among patients who received SCEMBLIX, 83% were exposed for 24 weeks or longer and 56% were exposed for 96 weeks or longer.</p><p>Serious adverse reactions occurred in 18% of patients who received SCEMBLIX. Serious adverse reactions in &ge; 1% included cardiac failure congestive (1.9%), pyrexia (1.9%), urinary tract infection (1.9%), headache (1.3%), and thrombocytopenia (1.3%). Two patients (1.3%) had a fatal adverse reaction, one each for mesenteric artery thrombosis and ischemic stroke.</p><p>Permanent discontinuation of SCEMBLIX due to an adverse reaction occurred in 8% of patients. Adverse reactions which resulted in permanent discontinuation of SCEMBLIX in &gt; 2% of patients included thrombocytopenia (3.2%) and neutropenia (2.6%).</p><p>Dosage interruptions of SCEMBLIX due to an adverse reaction occurred in 41% of patients. Adverse reactions which required dosage interruption in &gt; 5% of patients included thrombocytopenia (19%) and neutropenia (18%).</p><p>Dose reductions of SCEMBLIX due to an adverse reaction occurred in 6% of patients. Adverse reactions which required dose reductions in &gt; 1% of patients included thrombocytopenia (4.5%) and neutropenia (1.3%).</p><p>The most common (&ge; 20%) adverse reactions in patients who received SCEMBLIX were upper respiratory tract infections, musculoskeletal pain, headache, and fatigue.</p><p>The most common select laboratory abnormalities that worsened from baseline in &ge; 20% of patients who received SCEMBLIX were platelet count decreased, triglycerides increased, neutrophil count decreased, hemoglobin decreased, creatine kinase increased, alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased, uric acid increased, and lymphocyte count decreased.</p><p>Table 5 summarizes the adverse reactions in ASCEMBL.</p><p>Table 5: Adverse Reactions (&ge; 10%) in Patients with Ph+ CML in CP, Previously Treated with Two or More TKIs Who Received SCEMBLIX in ASCEMBL</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>SCEMBLIX </strong><strong>N = 156</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Bosutinib </strong><strong>N = 76</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Adverse</strong><strong> </strong><strong>Reaction</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4</strong></p><p><strong>%</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Infections</strong><strong> </strong><strong>and</strong><strong> </strong><strong>infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection<sup>a</sup></p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Musculoskeletal</strong><strong> </strong><strong>and</strong><strong> </strong><strong>connective</strong><strong> </strong><strong>tissue</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain<sup>b</sup></p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache<sup>c</sup></p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>General</strong><strong> </strong><strong>disorders</strong><strong> </strong><strong>and</strong><strong> </strong><strong>administration-site</strong><strong> conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>d</sup></p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Skin</strong><strong> </strong><strong>and</strong><strong> subcutaneous tissue disorders</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Rash<sup>e</sup></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Vascular</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypertension<sup>f</sup></p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>3.9</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Gastrointestinal</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea<sup>g</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>72</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain<sup>h</sup></p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>2.6</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Abbreviations: Ph+ CML in CP, Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP); TKIs, tyrosine kinase inhibitors.</p><p><sup>a</sup>Upper respiratory tract infection includes: nasopharyngitis, upper respiratory tract infection, rhinitis, pharyngitis, respiratory tract infection, and pharyngotonsillitis.</p><p><sup>b</sup>Musculoskeletal pain includes: pain in extremity, back pain, myalgia, non-cardiac chest pain, neck pain, bone pain, spinal pain, arthritis, musculoskeletal pain, and musculoskeletal chest pain.</p><p><sup>c</sup>Headache includes: headache and post-traumatic headache.</p><p><sup>d</sup>Fatigue includes: fatigue and asthenia.</p><p><!--[if gte vml 1]><v:group id="Group_x0020_3" o:spid="_x0000_s1026"
   style='position:absolute;left:0;text-align:left;margin-left:359.9pt;
   margin-top:13.4pt;width:4.45pt;height:11.55pt;z-index:-16881152;
   mso-wrap-distance-left:0;mso-wrap-distance-right:0' coordsize="56515,146685"
   o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_4" o:spid="_x0000_s1027" style='position:absolute;
    width:56515;height:146685;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="56515,146685" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m56387,l,,,146303r56387,l56387,xe" fillcolor="yellow" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="6" height="16" src="file:///C:/Users/ALMUHRE2/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><sup>e</sup>Rash includes: rash, rash maculopapular, dermatitis acneiform, rash pustular, eczema, dermatitis, skin exfoliation, dermatitis exfoliative generalized, rash morbilliform, drug eruption, erythema multiforme, and rash erythematous. <sup>f</sup>Hypertension includes: hypertension and hypertensive crisis.</p><p><sup>g</sup>Diarrhea includes: diarrhea and colitis.</p><p><sup>h</sup>Abdominal pain includes: abdominal pain, abdominal pain upper, abdominal discomfort, abdominal pain lower, abdominal tenderness, and epigastric discomfort.</p></td></tr></tbody></table><p>Clinically relevant adverse reactions in &lt; 10% of patients treated with SCEMBLIX in ASCEMBL included: cough, dyspnea, pleural effusion, dizziness, neuropathy peripheral, edema, pyrexia, vomiting, constipation, dyslipidemia, decreased appetite, pruritus, urticaria, lower respiratory tract infection, influenza, urinary tract infection, pneumonia, hemorrhage, arrhythmia (including electrocardiogram QT prolonged), palpitations, cardiac failure congestive, vision blurred, dry eye, hypothyroidism, and febrile neutropenia.</p><p>Table 6 summarizes the laboratory abnormalities in ASCEMBL.</p><p>Table 6: Select Laboratory Abnormalities (&ge; 10%) That Worsened from Baseline in Patients with Ph+ CML in CP, Previously Treated with Two or More TKIs Who Received SCEMBLIX in ASCEMBL</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>SCEMBLIX<sup>1</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Bosutinib<sup>1</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Laboratory</strong><strong> </strong><strong>Abnormality</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4</strong></p><p><strong>%</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Hematologic parameters</strong></p></td></tr><tr><td style="vertical-align:top"><p>Platelet count decreased</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Neutrophil count decreased Hemoglobin decreased</p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>54</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Lymphocyte count decreased</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>3.3</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>2.6</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Biochemical</strong><strong> </strong><strong>parameters</strong></p></td></tr><tr><td style="vertical-align:top"><p>Triglycerides increased</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>2.6</p></td></tr><tr><td style="vertical-align:top"><p>Creatine kinase increased</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase</p><p>(ALT) increased</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>16</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase (AST) increased</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>Uric acid increased</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>2.6</p></td></tr><tr><td style="vertical-align:top"><p>Phosphate decreased</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>7</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Corrected calcium decreased</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Lipase increased</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>4.5</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine increased</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Amylase increased</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Alkaline phosphatase (ALP) increased</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Bilirubin increased</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Cholesterol increased</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Potassium decreased</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>1</sup>The denominator used to calculate the rate for SCEMBLIX and bosutinib varied from 152 to 156 and 75 to 76, respectively, based on the number of patients with a baseline value and at least one post-treatment value.</p><p>CTCAE version 4.03.</p></td></tr></tbody></table><p><u>Description of selected adverse reactions</u></p><p><u>Adverse Reactions in Patients with Ph+ CML-CP with the T315I Mutation</u></p><p>The single-arm clinical trial enrolled patients with Ph+ CML-CP with the T315I mutation <em>(see section 5.1). </em>The safety population (received at least 1 dose of SCEMBLIX) included 48 patients with Ph+ CML-CP with the T315I mutation who received 200 mg of SCEMBLIX twice daily. Among these patients, 83% were exposed for 24 weeks or longer, and 75% were exposed for 48 weeks or longer.</p><p>Serious adverse reactions occurred in 23% of patients who received SCEMBLIX. Serious adverse reactions in &gt; 1% included abdominal pain (4.2%), vomiting (4.2%), pneumonia (4.2%), musculoskeletal pain</p><p>(2.1%), headache (2.1%), hemorrhage (2.1%), constipation (2.1%), arrhythmia (2.1%), and pleural effusion</p><p>(2.1%).</p><p>Permanent discontinuation of SCEMBLIX due to an adverse reaction occurred in 10% of patients. Adverse reactions which resulted in permanent discontinuation of SCEMBLIX in &gt; 2% of patients included pancreatic enzymes increased (2.1%).</p><p>Dosage interruptions of SCEMBLIX due to an adverse reaction occurred in 31% of patients. Adverse reactions which required dosage interruption in &gt; 5% of patients included pancreatic enzymes increased (17%) and thrombocytopenia (8%).</p><p>Dose reductions of SCEMBLIX due to an adverse reaction occurred in 23% of patients. Adverse reactions which required dose reductions in &gt; 1% of patients included pancreatic enzymes increased (10%), abdominal pain (4.2%), anemia (2.1%), blood bilirubin increased (2.1%), dizziness (2.1%), fatigue (2.1%),</p><p>hepatic enzymes increased (2.1%), musculoskeletal pain (2.1%), nausea (2.1%), neutropenia (2.1%),</p><p>pruritus (2.1%), and thrombocytopenia (2.1%).</p><p>The most common (&ge; 20%) adverse reactions in patients who received SCEMBLIX were musculoskeletal pain, fatigue, nausea, rash, and diarrhea.</p><p>The most common select laboratory abnormalities that worsened from baseline in &ge; 20% of patients who received SCEMBLIX were alanine aminotransferase (ALT) increased, lipase increased, triglycerides increased, hemoglobin decreased, neutrophil count decreased, lymphocyte count decreased, phosphate decreased, aspartate aminotransferase (AST) increased, amylase increased, platelet count decreased, and bilirubin increased.</p><p>&nbsp;</p><p>Table 7 summarizes adverse reactions in study X2101.</p><p>Table 7: Adverse Reactions (&ge; 10%) in Patients with Ph+ CML in CP with the T315I Mutation Who Received SCEMBLIX in X2101</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>SCEMBLIX</strong></p><p><strong>200 mg twice daily N = 48</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Adverse</strong><strong> </strong><strong>Reaction</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4</strong></p><p><strong>%</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal</strong><strong> </strong><strong>and</strong><strong> </strong><strong>connective</strong><strong> </strong><strong>tissue</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain<sup>a</sup></p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>4.2</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>General</strong><strong> </strong><strong>disorders</strong><strong> </strong><strong>and</strong><strong> </strong><strong>administration-site</strong><strong> conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>b</sup></p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Edema</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>4.2</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain<sup>c</sup></p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Skin</strong><strong> </strong><strong>and</strong><strong> subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash<sup>d</sup></p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache<sup>e</sup></p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory,</strong><strong> </strong><strong>thoracic,</strong><strong> </strong><strong>and</strong><strong> </strong><strong>mediastinal</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cough<sup>f</sup></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Vascular</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhage<sup>g</sup></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension<sup>h</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Infections</strong><strong> </strong><strong>and</strong><strong> </strong><strong>infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection<sup>i</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>aMusculoskeletal pain includes: pain in extremity, back pain, myalgia, musculoskeletal pain, non-cardiac chest pain, bone pain, arthritis, and musculoskeletal chest pain.</p><p>bFatigue includes: fatigue and asthenia.</p><p>cAbdominal pain includes: abdominal pain and hepatic pain.</p><p>dRash includes: rash, rash maculopapular, dermatitis acneiform, eczema, rash papular, skin exfoliation, and dyshidrotic eczema.</p><p>eHeadache includes: headache and migraine.</p><p>fCough includes: cough and productive cough.</p><p>gHemorrhage includes: epistaxis, ear hemorrhage, mouth hemorrhage, post procedural hemorrhage, skin hemorrhage, and vaginal hemorrhage.</p><p>hHypertension includes: hypertension and hypertensive crisis.</p><p>iUpper respiratory tract infection includes: upper respiratory tract infection, nasopharyngitis, rhinitis, and pharyngitis.</p></td></tr></tbody></table><p>&nbsp;</p><p>Clinically relevant adverse reactions in &lt; 10% of patients treated with SCEMBLIX in X2101 included: constipation, pancreatitis, pyrexia, dizziness, neuropathy peripheral, pneumonia, lower respiratory tract infection, dyspnea, pleural effusion, dry eye, vision blurred, arrhythmia, palpitations, cardiac failure congestive, decreased appetite, dyslipidemia, hypersensitivity, and urticaria.</p><p>Table 8 summarizes laboratory abnormalities in X2101.</p><p>Table 8: Select Laboratory Abnormalities (&ge; 10%) That Worsened from Baseline in Patients with Ph+ CML in CP with the T315I Mutation in X2101</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>SCEMBLIX<sup>1</sup></strong></p><p><strong>200 mg twice daily</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Laboratory</strong><strong> </strong><strong>Abnormality</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grade</strong><strong> </strong><strong>3-</strong><strong>4</strong></p><p><strong>%</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Hematologic parameters</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hemoglobin decreased</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>4.2</p></td></tr><tr><td style="vertical-align:top"><p>Neutrophil count decreased</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p>Lymphocyte count decreased</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>4.2</p></td></tr><tr><td style="vertical-align:top"><p>Platelet count decreased</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Biochemical</strong><strong> </strong><strong>parameters</strong></p></td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase (ALT) increased</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Potassium increased</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Triglycerides increased</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Lipase increased</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>21</p></td></tr><tr><td style="vertical-align:top"><p>Phosphate decreased</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Uric acid increased</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>4.2</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase (AST) increased</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Calcium corrected decreased</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine increased</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Amylase increased</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>Bilirubin increased</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Cholesterol increased</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Alkaline phosphatase (ALP) increased</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1</sup>The denominator used to calculate the rate was 48 based on the number of patients with a baseline value and at least one post-treatment value.</p><p>CTCAE version 4.03.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>o&nbsp; SFDA call center: 19999</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>o Toll Free Number: 8001240078</p><p>o&nbsp; Phone: +966112658100</p><p>o&nbsp; Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>- Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>To report any complaint(s): </strong>complaints.ksa@novartis.com</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies, asciminib has been administered at doses up to 280&nbsp;mg twice daily with no evidence of increased toxicity.</p><p>&nbsp;</p><p>General supportive measures and symptomatic treatment should be initiated in cases of suspected overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01EA06</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Asciminib is an ABL/BCR-ABL1 tyrosine kinase inhibitor. Asciminib inhibits the ABL1 kinase activity of the BCR-ABL1 fusion protein, by binding to the ABL myristoyl pocket. In studies conducted in vitro or in animal models of CML, asciminib showed activity against wild-type BCR-ABL1 and several mutant forms of the kinase, including the T315I mutation.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Exposure-Response Relationships</p><p>Over asciminib dosages of 10 mg to 200 mg twice daily (0.25 to 5 times the recommended 80 mg daily dosage), a lower exposure was associated with a smaller decrease in BCR-ABL1 level and a lower MMR rate at Week 24.</p><p>Over asciminib dosages of 10 mg to 280 mg twice daily (0.25 to 7 times the recommended 80 mg daily dosage), a higher exposure was associated with slightly higher incidence of some adverse reactions (e.g., Grade &ge; 3 lipase increase, Grade &ge; 3 hemoglobin decrease, Grade &ge; 2 ALT increase, Grade &ge; 2 AST increase, Grade &ge; 2 bilirubin increase, and any grade lipase increase).</p><p>&nbsp;</p><p>Cardiac Electrophysiology</p><p>Asciminib does not cause a large mean increase in QTc interval (i.e., &gt; 20 msec) at the maximum recommended clinical dosage (200 mg twice daily). Based on available clinical data, small mean QTc increase (&lt; 10 msec) cannot be excluded.</p><p>&nbsp;</p><p><u>Clinical Efficacy and Safety</u></p><p>&nbsp;</p><p>Newly Diagnosed Ph+ CML-CP</p><p>The efficacy of SCEMBLIX in the treatment of patients with newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) was evaluated in the multi-center, randomized, active-controlled, and open-label study ASC4FIRST (NCT04971226).</p><p>In this study, a total of 405 patients were randomized in a 1:1 ratio to receive either SCEMBLIX or investigator selected tyrosine kinase inhibitors (IS-TKIs). Prior to randomization, the investigator selected the TKI (imatinib, nilotinib, dasatinib, or bosutinib) to be used in the event of randomization to the comparator arm, based on patient characteristics and comorbidities. Patients were stratified according to EUTOS long-term survival (ELTS) risk group (low, intermediate, high), and pre-randomization selection of TKI (imatinib or other TKIs stratum composed of nilotinib, dasatinib, and bosutinib). Patients received either SCEMBLIX or IS-TKIs, and continued treatment until unacceptable toxicity or treatment failure occurred.</p><p>Patients were 37% female and 63% male with median age 51 years (range, 18 to 86 years). Of the 405 patients, 24% were 65 years or older, while 6% were 75 years or older. Patients were White (54%), Asian (44%), Black or African American (1%), and 1% unknown.</p><p>Of the 405 patients, 200 received SCEMBLIX, while 201 received IS-TKIs. Of the 201 patients receiving IS-TKIs, 99 received imatinib, 49 received nilotinib, 42 received dasatinib, and 11 received bosutinib. Four patients did not receive any treatment.</p><p>The median duration of treatment was 70 weeks (range, 1 to 108 weeks) for patients receiving SCEMBLIX, and 64 weeks (range, 1 to 103 weeks) for patients receiving IS-TKIs. By 48 weeks, 90% of patients on SCEMBLIX, and 81% of patients on IS-TKIs were still receiving treatment.</p><p>The main efficacy outcome was major molecular response rate (MMR) at 48 weeks. Efficacy was established based on SCEMBLIX compared to IS-TKIs and SCEMBLIX compared to IS-TKIs within the imatinib stratum. The main efficacy outcomes from ASC4FIRST are summarized in Table 10.</p><p>Table 10: Efficacy Results in Patients with Newly Diagnosed Ph+ CML-CP (ASC4FIRST)</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>SCEMBLIX</strong></p><p><strong>80 mg once daily</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>IS-TKIs<sup>a</sup></strong></p><p><strong>100-400 mg once or twice daily</strong></p></td><td style="vertical-align:top"><p><strong>Difference </strong><strong>(95% CI)<sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>p-value</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All patients (N = 204)</strong></p></td><td style="vertical-align:top"><p><strong>Imatinib</strong></p><p><strong>stratum </strong><strong>(N = 102)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>MMR rate, % (95% CI) at 48 weeks</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>All patients (N = 201)</strong></p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>49</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>19</p></td><td rowspan="2" style="vertical-align:top"><p>&lt; 0.001<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>(61, 74)</p></td><td style="vertical-align:top"><p>(42, 56)</p></td><td style="vertical-align:top"><p>(10, 28)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Imatinib stratum (N = 101)</strong></p></td><td style="vertical-align:top"><p>69</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>30</p></td><td rowspan="2" style="vertical-align:top"><p>&lt; 0.001<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>(59, 78)</p></td><td style="vertical-align:top"><p>(31, 50)</p></td><td style="vertical-align:top"><p>(17, 42)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Abbreviations: MMR, major molecular response (<em>BCR::ABL1</em><sup>IS</sup> &le; 0.1%); IS-TKIs, investigator selected tyrosine kinase inhibitors.</p><p><sup>a</sup>IS-TKIs include imatinib (400 mg once daily) and other TKIs of nilotinib (300 mg twice daily), dasatinib (100 mg once daily) or bosutinib (400 mg once daily).</p><p><sup>b</sup>Estimated using a common risk difference stratified by PRS-TKI and baseline ELTS risk groups.</p><p><sup>c</sup>Adjusted p-value using a Cochran-Mantel-Haenszel 1-sided test stratified by PRS-TKI and baseline ELTS risk groups.</p><p><sup>d</sup>Adjusted p-value using a Cochran-Mantel-Haenszel 1-sided test stratified by baseline ELTS risk groups.</p></td></tr></tbody></table><p>MMR rates at 48 weeks in patients receiving SCEMBLIX and IS-TKIs within the other TKIs stratum were 66% (95% CI: 56%, 75% ) and 58% (95% CI: 48%, 68% ), respectively.</p><p>Median time to MMR in patients receiving SCEMBLIX, IS-TKIs, and IS-TKIs within the imatinib stratum were: 24 weeks (95% CI: 24 to 25 weeks), 36 weeks (95% CI: 36 to 49 weeks), and 49 weeks (95% CI: 36 to 60 weeks), respectively.</p><p>&nbsp;</p><p><strong><u>Ph+ CML-CP, Previously Treated with Two or More TKIs</u></strong></p><p>The efficacy of SCEMBLIX in the treatment of patients with Ph+ CML-CP, previously treated with two or more TKIs was evaluated in the multi-center, randomized, active-controlled, and open-label study ASCEMBL (NCT03106779).</p><p>In this study, a total of 233 patients were randomized in a 2:1 ratio and stratified according to major cytogenetic response (MCyR) status to receive either SCEMBLIX 40 mg twice daily (N = 157) or bosutinib 500 mg once daily (N = 76). Patients continued treatment until unacceptable toxicity or treatment failure occurred.</p><p>Patients were 52% female and 48% male with a median age of 52 years (range, 19 to 83 years). Of the 233 patients, 19% were 65 years or older, while 2.6% were 75 years or older. Patients were White (75%), Asian (14%), and Black or African American (4.3%). Of the 233 patients, 81% and 18% had Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, respectively. Patients who had previously received 2, 3, 4, or 5 or more prior lines of TKIs were 48%, 31%, 15%, and 6%, respectively. The median duration of treatment was 103 weeks (range, 0.1 to 201 weeks) for patients receiving SCEMBLIX and 31 weeks (range, 1 to 188 weeks) for patients receiving bosutinib.</p><p>The main efficacy outcomes from ASCEMBL are summarized in Table 11.</p><p>&nbsp;</p><p>Table 11: Efficacy Results in Patients with Ph+ CML-CP, Previously Treated with Two or More TKIs (ASCEMBL)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>SCEMBLIX</strong></p><p><strong>40 mg twice daily</strong></p></td><td style="vertical-align:top"><p><strong>Bosutinib </strong><strong>500 mg</strong></p><p><strong>once</strong><strong> </strong><strong>daily</strong></p></td><td style="vertical-align:top"><p><strong>Difference </strong><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>p-</strong><strong>value</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>MMR rate,</strong></p></td><td style="vertical-align:top"><p>N = 157</p></td><td style="vertical-align:top"><p>N = 76</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>% (95% CI)</strong></p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>12<sup>a</sup></p></td><td style="vertical-align:top"><p>0.029<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>at 24 weeks</strong></p></td><td style="vertical-align:top"><p>(19, 33)</p></td><td style="vertical-align:top"><p>(6.5, 23)</p></td><td style="vertical-align:top"><p>(2.2, 22)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>MMR rate,</strong></p></td><td style="vertical-align:top"><p>N = 157</p></td><td style="vertical-align:top"><p>N = 76</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>% (95% CI)</strong></p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>22<sup>a</sup></p></td><td style="vertical-align:top"><p>0.001<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>at 96 weeks</strong></p></td><td style="vertical-align:top"><p>(30, 46)</p></td><td style="vertical-align:top"><p>(8, 26)</p></td><td style="vertical-align:top"><p>(11, 33)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>CCyR rate,</strong></p></td><td style="vertical-align:top"><p>N = 103<sup>c</sup></p></td><td style="vertical-align:top"><p>N = 62<sup>c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>% (95% CI)</strong></p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>17</p></td></tr><tr><td style="vertical-align:top"><p><strong>at 24 weeks</strong></p></td><td style="vertical-align:top"><p>(31, 51)</p></td><td style="vertical-align:top"><p>(14, 37)</p></td><td style="vertical-align:top"><p>(3.6, 31)</p></td></tr><tr><td style="vertical-align:top"><p><strong>CCyR rate,</strong></p></td><td style="vertical-align:top"><p>N = 103<sup>c</sup></p></td><td style="vertical-align:top"><p>N = 62<sup>c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>% (95% CI)</strong></p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>24<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>at 96 weeks</strong></p></td><td style="vertical-align:top"><p>(30, 50)</p></td><td style="vertical-align:top"><p>(8, 28)</p></td><td style="vertical-align:top"><p>(10, 37)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Abbreviations: MMR, major molecular response (<em>BCR-ABL1</em><sup>IS</sup> &le; 0.1%); CCyR, complete cytogenetic response (0% of Philadelphia-positive metaphases in bone marrow aspirate with at least 20 examined).</p><p><sup>a</sup>Estimated using a common risk difference stratified by baseline major cytogenetic response status. <sup>b</sup>Estimated using a Cochran-Mantel-Haenszel two-sided test stratified by baseline major cytogenetic response status.</p><p><sup>c</sup>CCyR analysis based on patients who were not in CCyR at baseline.</p></td></tr></tbody></table><p>With a median duration of follow-up of 28 months (range: 1 day to 45 months), the median duration of response for patients treated with SCEMBLIX had not yet been reached.</p><p>&nbsp;</p><p><strong><u>Ph+ CML-CP with the T315I Mutation</u></strong></p><p>The efficacy of SCEMBLIX in the treatment of patients with Ph+ CML-CP with the T315I mutation was evaluated in a multi-center open-label study CABL001X2101 (NCT02081378). Testing for T315I mutation utilized a qualitative p210 BCR-ABL1 mutation test on peripheral blood using Sanger Sequencing.</p><p>Efficacy was based on 45 patients with Ph+ CML-CP with the T315I mutation who received SCEMBLIX at a dose of 200 mg twice daily. Patients continued treatment until unacceptable toxicity or treatment failure occurred.</p><p>Of the 45 patients, 80% were male and 20% female; 31% were 65 years or older, while 9% were 75 years or older with a median age of 54 years (range, 26 to 86 years). The patients were White (47%), Asian (27%), and Black or African American (2.2%), and 24% were unreported or unknown. Seventy-three percent and 27% of patients had ECOG performance status 0 and 1, respectively. Patients who had previously received 1, 2, 3, 4, and 5 or more TKIs were 18%, 31%, 36%, 13%, and 2.2%, respectively. MMR was achieved by</p><p>24 weeks in 42% (19/45, 95% CI: 28% to 58%) of the 45 patients treated with SCEMBLIX. MMR was</p><p>achieved by 96 weeks in 49% (22/45, 95% CI: 34% to 64%) of the 45 patients treated with SCEMBLIX. The median duration of treatment was 108 weeks (range, 2 to 215 weeks).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Asciminib steady-state exposure (AUC and C<sub>max</sub>) increase slightly more than dose proportional across the dose range of 10 to 200 mg (0.25 to 5 times the recommended 80 mg daily dosage) administered once or twice daily.</p><p>Pharmacokinetic parameters are presented as geometric mean (CV%) unless otherwise stated. The steady state C<sub>max</sub> and AUC<sub>tau</sub> of asciminib at recommended dosages are listed in Table 7.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 7: Steady State<sup>a</sup> Asciminib Exposure at Recommended Dosages</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Asciminib Dosage</strong></p></td><td><p><strong>C</strong><strong><sub>max</sub></strong><strong> (ng/mL)</strong></p></td><td><p><strong>AUC<sub>tau</sub><sup>b</sup> (ng*h/mL)</strong></p></td><td style="vertical-align:top"><p><strong>Accumulation Ratio</strong></p></td></tr><tr><td><p>80 mg once daily</p></td><td><p>1781 (23%)</p></td><td><p>15112 (28%)</p></td><td><p>1.30</p></td></tr><tr><td><p>40 mg twice daily</p></td><td><p>793 (49%)</p></td><td><p>5262 (48%)</p></td><td><p>1.65</p></td></tr><tr><td><p>200 mg twice daily</p></td><td><p>5642 (40%)</p></td><td><p>37547 (41%)</p></td><td><p>1.92</p></td></tr><tr><td colspan="4"><p><sup>a</sup>Steady state is achieved within 3 days.</p><p><sup>b</sup>AUC<sub>tau</sub> represents AUC<sub>0-12h</sub> for twice daily dosing and AUC<sub>0-24h</sub> for once daily dosing.</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Absorption</u></p><p>The median (range) T<sub>max</sub> of asciminib is 2.5 hours (2 to 3 hours).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Effect of Food</em></p><p>The AUC and C<sub>max</sub> of asciminib decreased by 62% and 68%, respectively, with a high-fat meal (1000 calories, 50% fat) and by 30% and 35%, respectively, with a low-fat meal (400 calories, 25% fat) compared to the fasted state following administration of SCEMBLIX.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>The apparent volume of distribution of asciminib at steady state is 151 L (135%). Asciminib is the main circulating component in plasma (93% of the administered dose).</p><p>Asciminib is 97% bound to human plasma proteins <em>in vitro</em>.</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p>&nbsp;</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The total apparent clearance of asciminib is 6.7 L/hour (48%) at 40 mg twice daily and 80 mg once daily, and 4.1 L/hour (38%) at 200 mg twice daily. The terminal elimination half-life of asciminib is 5.5 hours (38%) at 40 mg twice daily and 80 mg once daily, and 9.0 hours (33%) at 200 mg twice daily.</p><p><em>Metabolism</em></p><p>Asciminib is metabolized by CYP3A4-mediated oxidation, UGT2B7- and UGT2B17-mediated glucuronidation.</p><p><em>Excretion</em></p><p>Eighty percent (57% as unchanged) and 11% (2.5% as unchanged) of the asciminib dose were recovered in the feces and in the urine of healthy subjects, respectively, following oral administration of a single 80 mg dose of radio-labeled asciminib.</p><p>&nbsp;</p><p>Asciminib is eliminated by biliary secretion via breast cancer-resistant protein (BCRP).</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Specific Populations</u></p><p>No clinically significant differences in the pharmacokinetics of asciminib were observed based on sex, age (20 to 88 years), race (Asian 20%, White 70%, Black/African American 4%), or body weight (42 - 184 kg), mild to moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m<sup>2</sup>), or mild (total bilirubin &le; ULN and AST &gt; ULN or total bilirubin &gt; 1 to 1.5 times ULN and any AST) to moderate (total bilirubin &gt; 1.5 to 3 times ULN and any AST) hepatic impairment.</p><p><em>Patients with</em><em> Renal Impairment</em></p><p>Asciminib AUC<sub>inf</sub> and C<sub>max</sub> are increased by 57% and 6%, respectively, in subjects with eGFR between 13 to &lt; 30 mL/min/1.73 m<sup>2</sup> and not requiring dialysis compared to subjects with normal renal function (eGFR &ge; 90 mL/min/1.73 m<sup>2</sup>) following oral administration of a single 40 mg dose of SCEMBLIX. The exposure changes in patients with severe renal impairment are not considered clinically meaningful.</p><p><em>&nbsp;</em></p><p><em>Patients with</em><em> Hepatic Impairment</em></p><p>Asciminib AUC<sub>inf</sub> and C<sub>max</sub> are increased by 33% and 4%, respectively, in subjects with severe hepatic impairment (total bilirubin &gt; 3 times ULN and any AST), compared to subjects with normal hepatic function (total bilirubin &le; ULN and AST &le; ULN) following oral administration of a single 40 mg dose of SCEMBLIX. The exposure changes are not considered clinically meaningful.<em> </em></p><p><u>Drug Interaction Studies </u></p><p><em>Clinical Studies and Model-Informed Approaches </em></p><p><u>Drugs That Affect Asciminib Plasma Concentration<em> </em></u></p><p><em>Strong CYP3A Inhibitors: </em>The asciminib AUC<sub>inf</sub> and C<sub>max</sub> increased by 36% and 19%, respectively, following coadministration of a single SCEMBLIX dose of 40 mg with a strong CYP3A4 inhibitor (clarithromycin). No clinically significant differences in the pharmacokinetics of asciminib were observed when coadministered with itraconazole, which is also a strong CYP3A4 inhibitor.</p><p><em>Strong CYP3A Inducers: </em>Concomitant use of strong CYP3A inducers with SCEMBLIX has not been fully characterized.</p><p><em>Itraconazole Oral Solution</em>: Coadministration of multiple doses of itraconazole oral solution containing hydroxypropyl-&beta;-cyclodextrin with a single SCEMBLIX dose of 40 mg decreased asciminib AUC<sub>inf</sub> and C<sub>max</sub> by 40% and 50%, respectively. Concomitant use of oral products containing hydroxypropyl-&beta;-cyclodextrin with SCEMBLIX other than itraconazole oral solution has not been fully characterized.</p><p><em>Imatinib: </em>The asciminib AUC<sub>inf</sub> and C<sub>max</sub> increase by 108% and 59%, respectively following coadministration of a single SCEMBLIX dose of 40 mg with imatinib (an inhibitor of BCRP, CYP3A4, UGT2B17, and UGT1A3/4). The exposure changes are not considered clinically meaningful.<em> </em>Concomitant use of imatinib with SCEMBLIX at 200 mg twice daily has not been fully characterized.</p><p><em>Other Drugs:</em> No clinically significant differences in the pharmacokinetics of asciminib were observed when coadministered with rabeprazole (acid-reducing agent) and quinidine (P-gp inhibitor).<em> </em></p><p><u>Drugs That are Affected by Asciminib</u></p><p><em>CYP3A4 Substrates:</em> The midazolam AUC<sub>inf</sub> and C<sub>max</sub> increased by 28% and 11%, respectively, following coadministration of a CYP3A4 substrate (midazolam) with SCEMBLIX 40 mg twice daily. The midazolam AUC<sub>inf</sub> and C<sub>max</sub> increased by 24% and 17%, respectively, following coadministration with SCEMBLIX at 80 mg once daily and 88% and 58%, respectively, at 200&nbsp;mg twice daily. <em>&nbsp;</em></p><p><em>CYP2C9 Substrates:</em> The S-warfarin AUC<sub>inf</sub> and C<sub>max</sub> increased by 41% and 8%, respectively, following coadministration of CYP2C9 substrate (warfarin) with SCEMBLIX at 40 mg twice daily. The S-warfarin AUC<sub>inf</sub> and C<sub>max</sub> increased by 52% and 4%, respectively, following coadministration with SCEMBLIX at 80 mg once daily and 314% and 7%, respectively, at 200&nbsp;mg twice daily.</p><p><em>CYP2C8 Substrates:</em> The repaglinide (substrate of CYP2C8, CYP3A4, and OATP1B) AUC<sub>inf</sub> and C<sub>max</sub> increased by 8% and 14%, respectively, following coadministration of repaglinide with SCEMBLIX 40 mg twice daily. The repaglinide AUC<sub>inf</sub> and C<sub>max</sub> increased by 12% and 8%, respectively, following coadministration with SCEMBLIX at 80 mg once daily and 42% and 25%, respectively, at 200 mg twice daily. The rosiglitazone (substrate of CYP2C8 and CYP2C9) AUC<sub>inf</sub> and C<sub>max</sub> increased by 20% and 3%, respectively, following coadministration of rosiglitazone with SCEMBLIX 40 mg twice daily. The rosiglitazone AUC<sub>inf</sub> and C<sub>max</sub> increased by 24% and 2%, respectively, following coadministration with SCEMBLIX at 80 mg once daily and 66% and 8%, respectively, at 200 mg twice daily.</p><p><em>P-gp Substrates</em>: Coadministration of SCEMBLIX with a drug that is a substrate of P-gp may result in a clinically relevant increase in the plasma concentrations of P-gp substrates, where minimal concentration changes may lead to serious toxicities.</p><p><em><u>In Vitro Studies</u></em></p><p><em>CYP450 and UGT Enzymes</em></p><p>Asciminib may reversibly inhibit UGT1A1 at plasma concentrations reached at a total daily dose of 80 mg and 200 mg twice daily. In addition, asciminib may reversibly inhibit CYP2C19 at concentrations reached at 200 mg twice daily dose<em>.</em></p><p><em>Transporter Systems</em></p><p>Asciminib is a substrate of BCRP and P-gp. Asciminib inhibits BCRP, P-gp, OATP1B1, OATP1B3, and OCT1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenesis, Mutagenesis, Impairment of Fertility.</p><p>In a 2-year carcinogenicity study, rats were administered oral doses of asciminib at 20, 66, and 200 mg/kg/day in males and 10, 30, and 66 mg/kg/day in females. Asciminib induced a statistically significant increase in the incidence of benign Sertoli cell tumors in the ovaries of high-dose females. The exposures to asciminib (AUC) in female rats at 66 mg/kg/day were approximately 8-fold or 6-fold higher than the exposure (AUC) achieved in patients at the dose of 40 mg twice daily or 80 mg once daily, respectively, and equivalent to those achieved in patients at the dose of 200 mg twice daily. The clinical relevance of these findings is currently unknown.</p><p>Asciminib was not genotoxic in an in vitro bacterial mutagenicity (Ames) assay, an in vitro micronucleus assay in human peripheral blood lymphocytes (HPBL), or an in vivo rat peripheral blood reticulocyte micronucleus assay.</p><p>In a combined male and female fertility and early embryonic development study in rats, animals were administered asciminib doses of 10, 50, or 200 mg/kg/day orally. Male animals were dosed once daily for at least 28 days prior to mating, during the 2-week mating period, and until terminal necropsy (Days 63- 67). Female animals were dosed once daily for the 2-week premating period, during the 2-week mating period, and through gestation day (GD) 6. Decreased sperm count and motility were observed at 200 mg/kg/day. While there were no effects on fertility indices or conception rates, a decreased mean number of live embryos was observed at 200 mg/kg/day and was attributed to a lower number of implantations and an increased number of early resorptions. Increased early resorptions were also observed in the embryo- fetal development study in rabbits (see section 4.6).</p><p>At the dose of 200 mg/kg, the AUC exposures were approximately 19-fold, 13-fold, or 2-fold higher than those achieved in patients at the 40 mg twice daily, 80 mg once daily, or 200 mg twice daily doses, respectively.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Scemblix 20&nbsp;mg and 40&nbsp;mg film‑coated tablets</u></p><p>&nbsp;</p><p>Lactose monohydrate</p><p>Microcrystalline cellulose (E460i)</p><p>Hydroxypropylcellulose (E463)</p><p>Croscarmellose sodium (E468)</p><p>Polyvinyl alcohol (E1203)</p><p>Titanium dioxide (E171)</p><p>Magnesium stearate</p><p>Talc (E553b)</p><p>Colloidal silicon dioxide</p><p>Lecithin (E322)</p><p>Xanthan gum (E415)</p><p>Iron oxide red (E172)</p><p>&nbsp;</p><p><u>Scemblix 20</u><u>&nbsp;</u><u>mg film‑coated tablets only</u></p><p>&nbsp;</p><p>Iron oxide yellow (E172)</p><p>&nbsp;</p><p><u>Scemblix 40</u><u>&nbsp;</u><u>mg film‑coated tablets only</u></p><p>&nbsp;</p><p>Iron oxide black (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Scemblix is supplied in HDPE bottle + dessicant containing 60&nbsp;film‑coated tablets.</p><p>&nbsp;</p><p>The following pack sizes are available:</p><p>Packs containing 60&nbsp;film‑coated tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The marketing Authorization Holder for this product is Novartis Europharm Limited, Ireland

www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>